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Modulating Aged Macrophages and Osteoprogenitors with a Calcium Phosphate Drug 
Delivery System 
 Jumana Rajeh Alhamdi,  PhD, University of Connecticut, 2018 
ABSTRACT  
Older adults suffer from weakened and delayed bone healing due to age-related 
alterations in bone cells and in the immune system. Given the interaction between the immune 
system and skeletal cells, therapies that address deficiencies in both the skeletal and the immune 
system are required to effectively treat bone injuries of older patients. The sequence of 
macrophage activation observed in healthy tissue repair involves a transition from a pro-
inflammatory state followed by a pro-reparative state. In older patients, inflammation is slower 
to resolve and impedes healing. The goal of this dissertation was to design a novel drug delivery 
system for temporal guidance of the polarization of macrophages using bone grafting materials.  
A biomimetic calcium phosphate coating (bCaP) physically and temporally separated the pro-
inflammatory stimulus interferon-gamma (IFN) from the pro-reparative stimulus simvastatin 
(SIMV). Effects on both human (THP-1) and aged mouse bone marrow macrophages were 
tested. Sequential M1-to-M2 activation was achieved with both cell types. Successful osteogenic 
differentiation of human osteoprogenitors derived from older patients was confirmed with the 
delayed delivery of SIMV from bCaP. These results suggest that this novel immunomodulatory 
drug delivery system holds potential for controlling macrophage activation to maximize older 
patient bone healing. In vitro studies prove our hypothesis and show successful macrophage 
phenotype modulation and improved in vitro osteogenesis in preparation for future in vivo 
studies.  
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 رسالة شكر وتقدير
لت  ككتل لاتاا ال أتل أن كتت  دون إشترا اذ أستتذتيي التدكتو ل لي تذ كتوون التتي أولاً وقبل كل شيء، أود أن أبدأ بتوجيه الشكر إلى 
لقد كذن شر ذ ًأن أكتون اذلبتاتذ. واود اك تذ ان أشتكرلذ دعتى ددأاتذ ويشتيي اذ لتي لعبقتذء وافقت  ًىتل    تي  تتى  تي يوجيااذ. و
البحث صرادذ. دعى  غ  ال دكد ىل الاجتأذدذت التي يأت، والحذج  إلى إ اذء كتذب  اعب الأنح، والأو اق ال عأيت  أوقذت كون 
التتي يحتتذا  التتي يحتتذا الأراج ت ، والأتايأرات التتي أ تذجتت يراستاذ، والتد وت التتي يحتتذا التتد كل، والحعقتذت الد استي 
لح و ، كنت دائأذ ًأش ر أن بذىكذ ي أن أارق بذب الأستذتل كتوون، وأ اتذ ستو الإست ذ  ، أو الأ داث ال ذئعي  التي يتطعب ا
دعى ىواصع  ىتح زل ًوىتشي   ًستأخا ىل وقتاذ الثأيل جزءاً للإجذب  دعى أسألتي.   لقد أبقذ ي ش و ي بتعك الألأي  بذلن ب  لاذ 
دنتدىذ كت عتا الأىتر  ل ال عأتي الحتحيح، والتحتدث بثقت بحثي. لقد ج عتني الأستذتل كوون كذيبذ ًأ  ل، ودعأتني أن أاتر  ال تاا
بذل ع ، وقدىت لي دائأذ ىع  حذئح إكيذبي  ىثل "  ض ال كرل لتيل ستوإ إدتذدل يوجيته" و"ال شتل لتو اللتف الأول  تي التت ع ". 
 وأ ذ أك ذ ًىأتن  لعأثذل الرائع الاي قدىته لي كذىرأل  ذجح   ي الاندس  وكأستذته. 
 
التاكل أبتدوا الأنذقشت  لاتاا البحتث ور الأسذيال الدكتو  لرلتي، والتدكتو  كأبتذ ، والتدكتو   تذكر أد تذء لينت   أود أك ذ ًأن أشك
ال دكد ىل الألا ظذت الأ يدل  ول دأعي، والتي سذددت  ي يشكيل لاه الأارو   ويح تيل  وديت  البحتث. أشتكرل  جتدا ًدعتى 
التي استلدىتاذ وكي ي  ينذسباذ ىتع الأاتذ  الأكبتر لعبحتث. أ تذ ىحظو ت  أن يقدك   اكتا  ىل خلال ىنذقشذت دقيق   ول البيذ ذت 
وأود أك ذ ًالأاتأيل بذلطعب  و يذ ا . ككون لدي ىثل لاه الأيأود  ىل ال عأذء الأتكيذء  ي لين  الأنذقش ، والاكل ل  أك ذ ىل 
ول القيأ  ىل أجل إكأذل يحتأي  وين يتا الد است   تويوجياذياذ أن أشكر الدكتو ل كذ ا سبيعر ىل جذى   د كك ل دعى ىدخلاياذ 
 أ ذ أقد  كل ى ذلأذيا  بذلوقت، والأ كذ ، والأدخلات لي ل ييرب  الدكتو اه بذلن ب  لي ييرب  أكثر غنًى.  الللاكذ العأ يه الكبير
 
الرائ ت . أ تذ ىأتنت  بشتكل ختذ  كأذ أقد  الأ ذددل التي قدىاذ أصدقذئي  ي جذى   كو كتيكت الاكل دززوا يعتك البيةت  الت عيأيت 
البشتركه وددأاتذ ختلال الأشتار الأياتدل القعيعت  الأذ تي .  الللاكذ العأ يه الكبيترلعدكتو ل كيعي لذولي لأ ذددياذ  ي ال أل دعى 
ات  أود أن أدرب دل يقدكري لعبيةت  الأأت ت  التتي جعبتاتذ التدكتو ل ألكتل دكأيترو التدكتو  بتراكل وكنتد ير لألتبتر البحتث وددأ
 الأ تأر.
 
التدكتو  ستنذن الحأتدي، لحبته الأ تتأر، وددأته، وي اأته لظرو تي أفنتذء ست يي لعححتول دعتى  أ ذ ىدكن  بشكر ختذ لزوجتي،
شاذدل الدكتو اه والتي ج عت أىر إ اذء لاه الرسذل  أىراً ىأكنذ.ً لقد ا تقتل فتلاث ىتراتن ىتل أجعتي، وكتذن دائأتذ ًىوجتودا ًلتددأي 
لل أستطيع الوصول إلى  اذك  ىطذ لاا الطركا الطوكل. أشكرك دعى كل ىذ قأت بته، وشتكرا ًلتك دعتى دندىذ كنت أدتقد أ ي 
دد  بحثي، وجعب ال شتذء لتي دنتدىذ كنتت أدأتل إلتى وقتتن ىتتأخر ىتل العيتل، ولت  يشتكض أبتدا ًىتل ق تذئي الكثيتر ىتل الوقتت  تي 
ب تيذ يك لع أتل لكتي  ق تي الأزكتد ىتل الوقتتض ى تذ.ً لقتد  الألتبر. أشكرك دعى دطلات  اذك  الإسبوع يعك دنتدىذ كنتت يأختا ي
كنت صبو اً جداً ى ي دندىذ كنت أش ر بذلإ بذا، وكنت يحت ل ى ي دندىذ يحدث أصترر الأشتيذء بشتكلن صتحيح، وكنتت لنتذك 
لك دعتى كو تك لتاا  دائأذ ًكعأذ كنُت  ي  ذج  لك للإستأذع لي. أ ذ أقد  كثيرا ًى ذلأتك  ي  يذيي وإكأذ ك بي و ي دأعي. شكراً 
 الزوا والحدكا الرائع.  
 
وأخيرا، أ ب أن أشير لعنذت الاكل ك نون الكثير بذلن ب  لي، ول  والدّي ، الأاندت  اجتح وإ تحتذ ، العتاان أ اترا الإكأتذن بتي 
دل الآختركل، وىنحذ ي الحرك   ي اختيذ  ىذ أ كد. أشكر والدي التاي ز ع  تّي  تب ال عت  ودعأنتي الطأتو ، والرغبت   تي ى تذد
أشتكر والتديي دعتى الحتب التاي لتيل لته  تدود، والردذكت ،  والت تحي  التتي  بذلأكذ تتت.وال أل دائأذ ًبيد  تى الناذك  للإ ت ذل 
قذىت باذ لتشكيل  يتذيي.  ن تكض كنتتض دوىتذ ًدعتى إستت داد للاستتأذع لتي. أشتكرك  دعتى وجتودك  لتشتيي ي دعتى كتل خطتول دعتى 
لتقدك  كل ىذكأكل لك  لتأكيل أبنذاك  دعى النيذ .  لل أكون قذد ل ًأبدا ًدعتى  د ىقتدا  الحتب والأتودل الطركا، ودعى إست دادك  
التتي غأرلتذ والتدي دعتي. كأتذ أيقتدى بذلشتكر إلتى دأتي الأانتدت دعتي الحأتدي، و ختذلتي الرذليت  شت ذع، وأختوايي  اإ و  تد 
 أ نوي. وزكنب، دعى  با  وددأا  ال
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young adult and old mice during culture on bCaP with 10 g SIMV below the bCaP barrier 
layer. The M1 stimuli LPS and IFNγ were in the culture medium for the first 3 days. (A-C) M1 
macrophage markers. (D, E) M2 macrophage markers. Data normalized to GAPDH and then 
expressed as fold change over M0 macrophages cultured on bCaP. * P< 0.05.  
Figure 4.1: Age-related changes in osteoprogenitors (A) RT-qPCR cytokines gene expression. 
older human osteoprogenitors, 73 years old, as compared to younger cells, 44 years old. Data 
presented as fold-change over 4hrs baseline. Statistical analysis was performed using GraphPad 
software. t: test analysis of each gene of young vs old was performed and a P< 0.05 was 
considered significantly different. (B) β-Galactosidase (SABG) senescent staining of 
Osteoprogenitors obtained from 78 Years old female bone chip cells culture Scale bar=200um. 
Figure 4.2: RT-qPCR cytokines gene expression of inflammatory cytokines of 66 years old 
human osteoprogenitors treated with SIMV-A. (A). Day 3 gene expression of inflammatory 
cytokines with SIMV-A given at 4hrs and continues twice a week until day 21. (B). Day 6 gene 
expression of inflammatory cytokines with SIMV-A given at day 3 continues twice a week until 
day 21. (C) Day 10 gene expression of inflammatory cytokines with SIMV-A given at day 7 
continues twice a week until day 21. Data presented as fold-change compared to 4hrs baseline. 
Statistical analysis was performed using GraphPad software. t: test analysis of each time point 
was performed and a P< 0.05 was considered significantly different. 
Figure 4.3: XO staining of human osteoprogenitor 66 years old , passage 2 seeded cells at 
15,000 cells/cm
2
, treated with SIMV-A at various timing. Green frame indicates the start time of 
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SIMV-A treatment. A) 0.5nM of simvastatin was pipetted after 4hrs of culture and continued 
twice a week until day 30. B) 0.5nM of simvastatin was pipetted on day 3 of culture and 
continued twice a week until day 30. C) 0.5nM or 10 nM of simvastatin was pipetted with 
osteogenic medium on day  7 of culture and continued twice a week until day 30. Scale bar 100 
um. 
Figure 4.4: Calcium content and gene expression of human osteoprogenitor 66 years old treated 
with SIMV-A at various timing showing enhanced osteogenesis by delayed SIMV-A as 
measured by (A) Calcium content on day 30 of culture. (B, C, D) Osteogenic genes (BSP, OCN 
and BMP-2) with low dose ,0.5nM, given at day 7 as compared to higher dose given at the same 
time. Data presented as fold-change compared to day 7 baseline. Statistical analysis was 
performed using GraphPad software. Two way ANOVA multiple comparison analysis was 
performed and a P< 0.05 was considered significantly different (*P< 0.05 , ****P= < 0.0001 ). 
Figure 4.5: Human osteoprogenitor 62 years old seeded on bCaP coated disks (C) or (S) 2 g or 
10 g SIMV-bCaP. (A) AlamarBlue cell proliferation assay (B) Gene expression anti-
inflammatory markers (IL1, IL6 and TNF) and pro-reparative  IL10. Data presented as fold-
change compared to control. Statistical analysis was performed using GraphPad software. Two 
way ANOVA multiple comparison analysis of each gene was performed and a P< 0.05 was 
considered significantly different. 
Figure 4.6: Osteogenic gene expression of Older human osteoprogenitor (62 YO) with delayed 
delivery of 2 g or 10 g SIMV from bCaP. (A) COL1A1. (B) BSP and (C) OCN. QPCR 
presented in fold change over day 7 (baseline) using 2-ΔΔCT. Statistical analysis was performed 
using GraphPad software. Unpaired t: test analysis of each time point was performed and a P< 
0.05 was considered significantly different. 
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Chapter 1 
Background and Specific Aims 
1.1 Introduction 
Bone is a unique organ that constantly remodels to maintain strong structure for daily 
forces applied to it. Our bones are a very important component of the oral and skeletal system 
and functionally interact with many other organs and tissues including bone marrow, lymphoid 
tissue, kidneys, adipose tissue, endocrine pancreas, brain and gonads [1]. Bone homeostasis is a 
continuous process composed of a balance between bone resorption and bone formation that is 
necessary to maintain structural integrity in response to loading, to repair damaged bone and to 
maintain normal physiological mineral levels.   
After the first few decades of life, there will be rapid decline in bone formation while 
bone resorption stays constant causing bone fragility and reduction in bone’s ability to heal [2-4]. 
Fractures and bone trauma can occur in people of any age; however, the number of broken bones 
increases with advanced age. In the older patients a combination of osteoporosis, decreased in 
bone density, and increased incidence of fall results in more bone injuries than younger patients 
[5, 6]. In addition to estrogen deficiency and inadequate intake of calcium and vitamin D, there 
are biological changes that occur in the older human associated with oxidative stresses and 
telomere shortening including cellular senescence, fat increase, chronic inflammation and 
reduced ability to fight infection [7].  
The growing older population, anticipated to reach more than 25% in 2060 in the US [8], 
makes it essential to develop therapeutic bone repair strategies specifically geared towards the 
2 
 
 
older person, in addition to treatments for the younger person. Understanding the bone 
regeneration capacity in the older patient is essential when developing therapeutic strategies for 
bone regeneration designed specifically to heal older bone in a timely manner. Therefore this 
chapter will focus on reviewing bone repair and healing affected by aging as well as strategies 
involved in localized delivery of biomolecules to counter age related decline of bone repair 
processes.  
This chapter begins by describing the immune system as related to bone repair, then the 
effect of the aging process on immune system with detailed information about how macrophages, 
bone homeostasis and repair are affected by age-associated inflammation. Existing strategies for 
countering the age-related decline of bone regeneration processes are described, particularly 
those involving localized delivery of molecules. In general, this dissertation focused on the 
development of a novel, biomimetic, a sequential delivery system capable of modulating 
macrophage phenotypes that could also  stimulate osteogenesis of older human osteoprogenitors. 
 
1.1.1 Bone Repair and Osteoimmunology 
1.1.1.1 Bone Repair phases  
Bone heals and repairs itself in two ways; primary (direct) fracture healing requires 
fixation, or secondary (indirect) fracture healing. Flat bone (craniofacial bones) heals via 
intramembranous healing while long bones heals via endochondral ossification. The majority of 
bones heal via the secondary (indirect) fracture healing which consists of both endochondral and 
intramembranous bone healing [9]. The indirect bone healing process involves events that 
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orchestrate five sequential and overlapping phases including hematoma formation, inflammation, 
soft callus formation, hard callus formation, and bone remodeling [10]. At the cellular level, the 
key players in the overall repair process include: inflammatory cells, vascular cells, 
osteoprogenitors, and osteoclast.  After bone injury, the very first response is hematoma 
formation which initiates the acute inflammatory stage.  This step is critical to bone healing 
because the hematoma initiates the signaling cascade that leads to successful bone formation 
[10]. 
The hematoma and inflammation phases involve immune cells from the peripheral blood, 
bone marrow cells and the invasion of inflammatory cells. The same pro-inflammatory stimuli 
that activate the clotting forming hematoma cascade also activate neutrophils, monocytes, and 
macrophages [11]. This cellular response results in the secretion of a wide range of cytokines and 
growth factors including macrophage colony stimulating factor (M-CSF), granulocyte colony-
stimulating factor (GCSF), stromal cell-derived factor-1 (SDF 1), interleukins-1 and -6 (IL1 and 
6), and tumor necrosis factor-α (TNF-α) [3, 12, 13]. The secretion of these factors facilitate the 
recruitment of additional inflammatory cells, and enhance the migration and invasion of essential 
mesenchymal stem cells (MSCs) [14, 15] 
In endochondral ossification, after the inflammatory phase, cartilaginous tissue will then 
form soft callus involving chondrocytes and fibroblasts to provide mechanical support to the 
fracture and act as a template for the bony callus. Chondrocytes are derived from mesenchymal 
progenitors their function appears by the synthesis of the cartilaginous matrix [16]. After all 
granulation tissues are replaced by cartilage, the chondrocytes undergo hypertrophy and 
mineralize the cartilaginous matrix before apoptosis. The proliferation and differentiation of both 
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fibroblast and chondrocyte are stimulated by the coordinated expression of growth factors 
including Transforming growth factor-beta (TGF-β2 and -β3), Platelet Derived Growth Factor 
(PDGF), fibroblast growth factor-1 (FGF-1), insulin-like growth factor (IGF) , and BMP family 
(BMP-2, -4, -5 and -6) [16]. These factors will then activate bone cells osteoblast to start the hard 
callus formation phase (forming mineralized bone matrix). The hard callus formation begins by 
the removal of the soft callus with revascularization [12].  
The hard callus can form in the absence of a cartilaginous template in intramembranous 
bone formation. During intramembranous ossification, compact and spongy bone forms directly 
from sheets of undifferentiated mesenchymal cells. The flat bones of the face, most of the cranial 
bones, and the clavicles are formed via intramembranous ossification. The process begins by 
inflammatory and mesenchymal cells migration to the injury site [17]. These MSCs will first 
proliferate and condense into compact nodules then they begin to differentiate into specialized 
cells (osteoprogenitors and then osteoblasts), early osteoblasts appear in a cluster called the 
ossification center. The osteoblasts secrete osteoid, uncalcified matrix consisting of collagen 
precursors and other organic proteins (type 1 collagen, bone sialoprotein and osteocalcin [18]), 
which calcifies with alkaline phosphatase enzyme [19], thereby entrapping the osteoblasts within 
the mineralized matrix. Once entrapped, the osteoblasts will then differentiate into osteocytes or 
mature bone cells [19]. As osteoblasts transform into osteocytes, osteoprogenitors in the 
surrounding connective tissue differentiate into new osteoblasts at the edges of the growing bone. 
At this point new bone formation is slowed and the compact MSCs surrounding the area of new 
bone formation will form the periosteum [20].   
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1.1.1.2 The Immune System 
The immune system is a host defense system that spread throughout the body and 
involves many types of cells, organs, proteins, and tissues. The immune system is typically 
divided into two categories: innate and adaptive immunity. Both systems work closely together 
and take on different tasks. Innate immunity refers to nonspecific defense mechanisms that come 
into play immediately or within hours of an antigen's appearance or injury in the body. These 
mechanisms include physical barriers such as skin, chemicals in the blood, and immune system 
cells that attack foreign cells in the body. Adaptive immunity refers to antigen-specific immune 
response [21].  
The majority of macrophages (innate immune cell) differentiate from circulating 
peripheral-blood mononuclear cells (PBMcs) that rapidly infiltrate the injury site or in response 
to inflammation [22-24]. Depending on the stage of healing at the injured site, inflammatory 
macrophages are polarized toward appropriate activation pathways that help to initiate and carry 
on the healing process. First, macrophages exhibit the pro-inflammatory phase, or cell 
recruitment phase, described as classically activated macrophages (commonly referred to as M1) 
[25]. Soon after cell recruitment phase, these M1 macrophages will be polarized to pro-
reparative phase described as alternative activated macrophages (commonly referred to as M2 
macrophages) to carry on the regeneration process [26]. M2 macrophages can be further 
subdivided into a series of distinct phenotypes, each with diverse functions ranging from tissue 
deposition to tissue remodeling [27, 28]. 
Successful macrophage activation outcomes can be measured by specific gene expression 
of each phenotype depending on macrophage source [29, 30]. M1 macrophages are usually 
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activated by IFN-γ and/or lipopolysaccharide (LPS) while M2 macrophages are activated by 
interleukins IL-4, IL-13 or IL-10 [29, 31]. M2a macrophages are characterized by their ability to 
inhibit inflammation and contribute to the stabilization of angiogenesis  [32]. The differences 
between two main subtypes of M2 macrophages, namely “M2a” macrophages stimulated by IL-4 
and “M2c” macrophages stimulated by IL-10, are not well understood. In fact, temporal gene 
expression analysis of human wound healing showed that M2c-related genes were upregulated at 
early times after injury, while M2a-related genes appeared at later stages or were downregulated 
after injury [27]. Overall, the polarization phenotype adopted by a macrophage can have a major 
influence over healing progression and outcome almost in all tissue repair process [33-36]. 
 
1.1.1.3 Osteoimmunology:  The Communication between the skeletal and immune systems 
At the molecular level, bone healing is driven by three main factors: pro-inflammatory 
cytokines and growth factors, pro-osteogenic factors, and angiogenic factors. The cross-talk 
between the inflammatory cells and osteoprogenitors introduced the term osteoimmunology 
which can be defined as an emerging field of research dedicated to the investigation of the 
interactions between the immune and skeletal systems [37]. These interactions are not only 
mediated by the release of cytokines and chemokines , by either inflammatory cells or bone cells, 
but also by direct cell-cell contact.  
After a bone injury, a variety of inflammatory cells infiltrate the injured site to initiate 
and stimulate the healing process. Inflammatory macrophages are essential components of the 
innate  immune systems also present throughout all bone healing phases secreting essential 
cytokines to promote vascularization, directed other cells migration, differentiation, and mediate 
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the overall healing process [38-40]. Various cytokines secreted by inflammatory cells play an 
important role in both formation and resorption. It has been demonstrated that Macrophages 
promote or suppress osteoclast activity through the secretion of TNF-α, IL-1, IL-6, and IFN-γ 
[41, 42]. In addition, TNF-𝛼 and IL-1 promote resorption activity of osteoclasts by increasing M-
CSF. M-CSF can bind to its receptor and stimulate differentiation via the actions of Receptor 
activator of nuclear factor kappa- ligand (RANKL) and osteoprotegerin (OPG), as a soluble 
decoy receptor for RANKL, which are a crucial regulator of osteoclastogenesis attributed to 
osteoclast differentiation and activation [43-48]. 
On the other hand, IL-10 has been considered as an important regulator of bone 
homeostasis, in homeostatic and inflammatory conditions. It has been demonstrated in multiple 
studies that IL-10 could directly inhibit osteoclasts formation by its direct action on osteoclast 
precursors [49-52] and by reducing nuclear factor of activated T cells (NFATC) expression [53, 
54]. In fact, enhanced osteoclastogenesis has been observed in cultures of bone marrow 
macrophages lacking IL-10 [55]. The molecular mechanism of this inhibition indicated that IL-
10 upregulated OPG expression but downregulated expression of the RANKL [56].  
Moreover, IL-10 can promote osteoblastic differentiation by the inhibition of TGF-β1 
production in murine bone marrow cells [57, 58]. Furthermore, it has been demonstrated there is 
a reduction of osteoblasts generation in bone marrow cell cultures obtained from IL-10 deficient 
mice with a reduction in bone mass, bone formation and increased bone mechanical fragility 
[59]. The study also emphasized that cytokines and inflammatory mediators, including TNF-α, 
IFN-γ, and IL6, had negative effects on the differentiation, proliferation, and function of 
osteoblasts in general [59]. Furthermore, IL10 can downregulate the synthesis of 
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proinflammatory cytokines and chemokines, such as IL-1, IL6, TNF-α and downregulate the 
synthesis of nitric oxide, gelatinase, and collagenase [60]. 
Interleukin 1beta (IL-1β), a cytokine secreted by macrophages, have the ability to 
stimulate osteoblasts proliferation and production of mineralized bone matrix and accelerate 
endochondral ossification process in mice [61]. Furthermore, in vitro study showed that IL-6 
inhibits bone nodule formation using rat calvarial cells and concluded that IL-6 may inhibit 
osteoblast differentiation [62]. Another cytokine that showed an effect on bone is IL-4. IL-4 
enhanced osteocalcin gene expression and alkaline phosphatase (ALP) activity but reduced Runt-
related transcription factor 2 (RUNX2) gene expression and bone nodule formation of human 
adipose stem cells (hASCs) [63].  
It can be concluded from the above studies there is a well-recognized link between the 
bone and the immune system and in recent years there has been a major effort to elucidate and 
understand this link. The co-regulation of the skeletal and immune systems emphasizes the 
extreme complexity of such an interaction. Their interdependency must be considered in 
designing therapeutic approaches for better bone repair outcome. In other words, it is necessary 
to think of the osteoimmune system as a complex physiological system involving the immune 
response and the host defense when implanting bone scaffold as well as the effect of specific 
molecules used to enhance the bone repair on the immune system and vice versa. 
 
1.1.2 Age-Related Alterations to Bone and Bone Healing Processes  
Age affects the microscopic and macroscopic structure of bone and leads to a reduction of total 
bone mass.  It’s well known that older bones are thinner and fragile with increased risk of bone 
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fractures and vertebral bone compression failures.  The reduced volume and strength of older 
bone creates challenges for orthopaedic and maxilla-facial craniofacial surgeons and 
prosthodontists (the dentists that place dental implants). With increasing age of the patient, 
surgeons conducting bone grafting procedures often utilize more plates and screws to stabilize 
the injured bone during healing.  The overall length of hospital stay increases with patient age 
and the lack of activity further leads to a decline in patient health [64]. Since the structural 
changes to bone with age result from cellular and molecular changes, this next section provides a 
detailed description of those alterations and thereby provides new focus areas for biomaterials 
research to address the source of the age-related bone frailty. 
 
1.1.2.1:  Effects of Age on bone cells: Osteoblasts, Osteoclasts and Osteocytes 
There are very few reports of age-specific functional changes to osteoblasts and 
osteoclasts; however, there is evidence for a reduced generation of osteoblasts and an increased 
generation of osteoclasts by the long-lived stem cells in bone as will be discussed in the next 
section. Osteocytes, also long-lived, are derived from terminally differentiated osteoblasts and 
are prone to aging related changes associated with estrogen reduction [65, 66]. Osteocytes also 
increasingly die with advancing age [67-69].  The reasons are many in addition to acute estrogen 
deficiency: increased oxidative stresses due to increased production of hydrogen peroxide and 
several other reactive oxygen species, treatment with glucocorticoids and an age-related increase 
of endogenous glucocortoids, and reduced physical activity. Their increased death with age has 
profound effects on bone because of their role in remodelling. Osteocyte death is directly 
associated with reduced bone strength in human patients that experience vertebral compression 
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fractures [70]. There are several mechanisms that contribute to the change in bone structure 
associated with osteocyte death. Osteocytes release factors that inhibit bone remodeling and their 
lack of production elevates resorption [71-73]. Dying osteocytes also release several factors that 
promote osteoclastogenesis including chemoattractants, prostaglandins, receptor activator for 
nuclear factor-kB (NF-kB) ligand and proinflammatory cytokines [74].  A reduction in bone 
vascularity and hydration is seen after osteocyte death, which reduces the strength of the 
materials bone are made of, such as the carbonated apatite crystals and collagen and 
proteoglycans [75]. The complicated signaling of the dying osteocyte has been summarized well 
[76].  Localized delivery strategies directed at supporting survival of the osteocyte could thus 
positively impact bone repair outcomes. 
 
1.1.2.2: Effects of Age on Mesenchymal Stromal Cells 
Mesenchymal stromal progenitor cells, found in stromal tissues throughout the body, 
abbreviated as MSCs in this dissertation, are one of the key cells that contribute to bone 
regeneration.  They produce factors that orchestrate immune cells involved in the healing process 
and differentiate into bone cells. An early promulgator of the trophic effects of stem cells from 
production of biomolecules was Dr. Arnold Caplan [77].  Early phases of successful bone 
healing include recruitment and proliferation of a sufficient number of MSCs along with a 
supportive blood supply. The number of MSCs obtained by marrow aspiration have been shown 
to decline with increased age of the donor bone marrow [78], indicating fewer MSCs are 
available to contribute to the healing process with age.  A study that quantified the number of 
MSCs from young and old human bone showed there is a decrease in osteoprogenitor cell 
number in 60 year old female patients as compared to younger patients [79]. The decline in 
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osteoprogenitor cell number resulted in decreased mineralization, protein levels of bone matrix 
and calcium content [78, 79].  
 
Further studies have confirmed the decrease in MSC number, responsiveness to signaling 
molecules, differentiation potential, and proliferative capacity in MSC derived from humans [80, 
81] and animals [82-84]. With advanced age, MSCs differentiate more into adipocytes, rather 
than into osteoblasts, and differentiation and responsiveness of MSCs to signaling molecules 
become impaired in patients of advanced age compared to MSCs derived from younger bone 
[85]. There is clear evidence that the decrease of osteoblastogenesis and the age-related changes 
in overall bone strength is due to the accumulation of bone marrow fat [86-88]. A general 
overview of the molecular and cellular alterations within bone that occur with age are 
summarized in Figure 1.   
 
Peffers et al. [89] used a systems biology technique to investigate the mRNA and DNA 
protein alterations in human MSCs with age.  Their study found evidence of alteration in both 
transcriptional and post-transcriptional levels in a number of transcription factors and alterations 
in energy metabolism and cell survival. Similar studies have been done to investigate gene 
expression changes in aged mouse MSCs and revealed significant stage-specific changes of 
genes associated with differentiation, cell cycle and growth factors [90]. Measurements of 
oxidative damage, ROS levels and nuclear proteins p21 and p53, which are markers of the aging 
process, were all increased in MSCs from older animals or humans [78]. Additional details about 
the alteration of MSCs with aging can be found in reviews by Kuang et al. [91], Bellantuono et 
al. [92] and Sui et al [93].  
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Overall, alterations with age give rise to an impaired role of MSCs during bone 
regeneration in older patients. The identification of age-associated changes to MSCs provides 
insights on how to improve their function during bone healing.  Autogenous MSCs from older 
patients used for stem cell therapies will likely benefit from being delivered to the wound site in 
scaffolds containing growth factors that address their deficiencies in proliferation or survival, as 
well as an osteoinductive agent.   
 
1.1.2.3: Growth Factors Associated with Bone Formation and Regeneration Decrease with Age 
Growth factors are soluble signaling molecules secreted by cells involved in bone repair 
such as inflammatory cells, fibroblasts, endothelial cells, MSCs and osteoblasts. The role of the 
following growth factors in bone repair is well established: bone morphogenetic proteins 
(BMPs), fibroblast growth factor (FGF), insulin-like growth factors (IGFs), platelet-derived 
growth factor (PDGF), transforming growth factor-β (TGF-β1 and TGF-β2) and vascular 
endothelial growth factor (VEGF).  The complicated interplay of many growth factors and their 
role in bone healing has been described well previously [11]. The sequence of growth factors 
present in the wound depends on the healing stage; for example, platelets release TGF-β1, 
PDGF, IGF-I and VEGF immediately after the bone injury and this causes other cells nearby to 
start to also secrete TGF-β and PDGF in response to the platelets.  This cascade of reactions is 
explained in the review by Barnes et al. [94].  BMPs may also stimulate the production of other 
growth factors important for bone regeneration; for example, BMP-2 stimulates the production 
of IGF and VEGF [95].  With regards to biomaterials delivery systems, each growth factor has a 
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specific role, at a specific time, in the regeneration process making it essential that each factor is 
presented in a biomimetic manner during healing in order to perform its role successfully.  
 
The regulatory effect of BMPs on bone and the importance of this factor during bone 
repair has been extensively reviewed by multiple scholars [96]. BMPs play a critical role in 
regulating cell growth, differentiation, and apoptosis of osteoblasts, chondrocytes and MSCs 
[97].  One change that occurs with aging is that an increased dose of BMP-2 must be used to 
obtain the same amount of bone within the same amount of time as a younger person or animal.  
Sixteen month old rats needed to be given six times more BMP-2 in order to form the same 
amount of ectopic bone as three month old rats [98]. Meyer et al. [99] showed 6 week old rats 
with fractures were restored to normal bone biomechanics after 4 weeks, while 1 year old rats 
took 26 weeks post-fracture to reach normal bone biomechanics.  Old rats in that study also had 
lower BMP-2 mRNA levels as compared to younger rats.  The need for higher doses in older 
patients means that delivery systems for older patients must be designed to achieve highly 
localized delivery, so that the off-target effects that occur with diffusion of BMP-2 away from 
the bone injury site is minimized. 
 
PDGF stimulates directed cell movement toward a gradient of PDGF, known as 
chemotaxis, as well as stimulating cell proliferation [100, 101]. It is another important growth 
factor contributing to the bone healing process.  PDGF is synthesized early during normally 
healing human bone fractures by various cell types like platelets, monocytes, macrophages, 
endothelial cells, and osteoblasts [102]. A more detailed description about the role of PDGF in 
bone can be found in Hollinger et al. [103] and Caplan et al. [104].  Like other factors related to 
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initiating the process of wound healing, aging has been found to alter the temporal profile of 
PDGF production and its receptors in mice within acute incisional wounds [105]. That study 
showed a delay and reduction in PDGF production and its receptors with increasing animal age 
that delays wound healing.  These studies indicate that PDGF supplementation would be an 
advantageous strategy for older patients when administered early in order to kick-start the wound 
healing process, but not continuously which would impair wound healing.   
 
FGF-2 is present during the early stages of fracture healing and guides angiogenesis and 
causes MSC proliferation [106-108]. FGFs are produced by many cell types such as monocytes, 
macrophages, mesenchymal cells, osteoblasts, and chondrocytes. In mice, disruption of a 
receptor for FGF-2, FGFR2, results in progressive osteopenia and decreased bone formation 
rates like that seen in older patients, suggesting FGF-2 changes are in part responsible for loss of 
bone mass in the elderly [109, 110].  Indeed, with age, FGF-2 and FGFR1 mRNA and protein in 
MSCs has been found to decrease with age [111], causing impairment in a number of essential 
signaling pathways involved in the bone repair process.  These studies further support the 
conclusions summarized in Figure 1. 
  
IGFs play an important role in normal bone development with null mutations of the genes 
encoding IGF-1 and 2 causing growth retardation, abnormalities in the growth plate, and 
decreased bone calcification in newborn mice [112]. IGF-I and TGF-β1 are essential growth 
factors needed during the early stage of fracture healing and their level is has been found to be 
reduced with aging.  Nicolas et al. [113] showed a linear decline in the skeletal content of IGF-I 
as well as a decrease TGF-β1 content using samples of femoral cortical bone from mainly men 
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and some women between the ages of 20-64 yr.  The circulating serum level of IGF-1 was 
reduced in women of age 70 or older who had experienced femoral bone mass reduction with 
aging [114], and in both elderly men and women who had a reduction in BMD [115]. 
Furthermore, the age-related decline in IGF-1 level reduced mechanical strength in human tibial 
posterior cortex bone samples which caused increased bone fracture rates [116]. 
 
To summarize, the aging process causes decreased production of TGF-β1, PDGF, IGF-I, 
FGF-2, BMP-2 and VEGF involved in wound healing and specifically bone repair.  The 
decreased presence of nearly every key growth factor involved in bone homeostasis, repair and 
regeneration contributes to age-related bone disease and slowed or difficult bone healing in the 
older patient.  Increasing cell production of growth factors in older patients or locally delivering 
either growth factors or drugs that lead to an increase in one or more growth factors is thus is an 
efficacious strategy to counter aging deficiencies and thereby enhance healing of elderly bone.  
 
1.1.3 Inflammaging and senescent cells Affect Bone Healing in Older Patients 
1.1.3.1:  Age-associated Increase of Pro-inflammatory Molecules Impedes Bone Healing 
No matter what the age is, after bone injury, an inflammation stage with marked cytokine 
production is necessary for initiation and progression of the normal healing process. The major 
source of cytokines are immune cells known as macrophages, except during aging when the 
inflamm-aging process results in a low-grade pro-inflammatory environment all the time from 
senescent cells throughout the body[117].  In bone, both macrophages formed from blood 
monocytes recruited to the injury site and resident bone macrophages are present throughout all 
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of the fracture healing phases.  They alter phenotype to promote various steps of tissue 
regeneration such directing MSC migration, proliferation, and differentiation, vascularization 
and remodeling as reviewed by [38, 40, 118, 119]. Understanding the relationship between 
macrophages and the skeletal system is essential for developing optimal therapeutic approaches 
to treat fractures in the elderly.  
 
The polarization of macrophages into the so-called “pro-inflammatory M1” and “pro-
reparative M2” phenotypes are both delayed in elderly patients and impair fracture healing of 
bone as reviewed in more detail by [120]. With age, the ratio of pro- inflammatory to anti-
inflammatory cytokines produced by macrophages increases and negatively impacts bone repair 
processes. TNF-α is significantly increased in M1 macrophages from aged rats as compared to 
those from young rats [121, 122].  TNF-α directly induces the marrow precursor cell 
differentiation into osteoclasts [123] and thus this helps to tip the homeostatic balance in bone 
towards resorption. There is also a decrease in systemic interferon-gamma (IFN) concentrations 
after fracture in older patients compared to young [124], which further increases resorption 
because IFN inhibits osteoclastic bone resorption [41, 42].  Aging bone marrow macrophages 
are more susceptible to oxidative stresses and they proliferate less in response to signals from 
granulocyte macrophage colony-stimulating factor (GM-CSF) [125].  M2 macrophages promote 
the ossification phase and studies in young mice show that the M2 phenotype can be increased 
with administration of interleukin 4 and 13 in fractures as a means to improve bone formation 
[126].  Modulating macrophages through delivery of cytokines is thus a strategy that could be 
pursued in older humans or animals to increase bone repair rates. 
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Cauley et al. [127] examined the circulating levels of pro-inflammatory cytokines (e.g. 
IL-6, TNF-, and IL-1) and their contribution to fractures in older humans. The study showed a 
strong correlation between high serum levels of inflammatory markers with incidence of 
fractures during a 5.8-yr follow-up period. Those with a higher level of inflammatory markers 
had the highest risk and history of fracture. Since IL-1 and IL-6 are potent promoters of 
osteoclast differentiation and activation[128, 129], their increase with age increases bone 
resorption and fracture risk. TNF- both stimulates bone resorption and inhibits new bone 
formation thus increasing fracture risk. The inducible nitric oxide synthesis pathway (iNOS) 
which inhibits the production of new osteoblasts and induces osteoblast apoptosis is activated 
through the effects of TNF- and IL-1 and further increases the higher activity of bone resorbing 
cells relative to bone forming cells. The pro-inflammatory environment in the body of the older 
patient thus contributes to increased fracture risk and the accelerates progressive loosening of 
total joint replacements that occurs in response to implant debris [130].  A low-grade pro-
inflammatory environment is a serious health concern because increased circulating cytokine 
levels have been shown to be strong, independent risk factors of morbidity and mortality in 
elderly populations [131].   
 
1.1.3.2: Cellular Senescence 
Aging is a result of predictable cellular death associated with a predetermined cellular 
lifespan known as the Hayflick limit [132]. The progressive decline in cellular function and 
eventual cell death is a result of cells wearing out from continued use and exposure to disease, 
oxidative stresses, DNA damage, altered chromatin structure, oncogene activation and telomere 
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dysfunction as reviewed by others [133-135]. These inducers cause cell senescence which is 
irreversible cell cycle arrest in which cells no longer divide, but remain viable and metabolically 
active.  In experiments with genetically altered mice in which senescent cells could be 
selectively killed, the negative effects of these cells and their association with many diseases of 
old age were proven [136].   
Senescent cells accumulate in multiple tissues in the body.  They are present in old mouse 
bones and bone marrow [137].  Senescent cells no longer function normally, but their inability to 
replicate is a better alternative than developing cancer from the cellular abnormality.  Senescent 
cells are actually protective if present in cancerous growths [138, 139].  
 
1.1.3.3: Effects of Cellular Senescence  
Changes in Systemic Levels of Growth Factors and Cytokines 
A subset of senescent cells develop a senescence associated secretory phenotype (SASP) 
and secrete numerous pro-inflammatory cytokines (e.g. Interleukin(IL)-1, -6, -8), chemokines 
and extracellular matrix degrading proteases [140].  Senescent cells thus contribute to the chronic 
low-level inflammation that develops in older people termed inflamm-aging [117].  
Inflammation goes up, but expression of pro-regenerative growth factors and extracellular matrix 
components required for wound healing and tissue regeneration is down-regulated[105]. Healing 
of bone and other tissues is negatively impacted by these changes.  The negative effects of 
senescent cell secretions and the reduction of pro-regenerative factors in the blood of older 
animals has been clearly demonstrated in mouse experiments in which the blood circulation of 
young and old mice is connected [141, 142]. This surgical technique is known as heterochronic 
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parabiosis.  Connection of an old mouse to the blood of a young mouse has been reported to 
reverse impaired age-related pathologies of aged mice including cardiac hypertrophy, slowed 
healing of muscle and bone injuries, and decline of hepatocyte proliferation [141, 142]. These 
experiments support the idea that reductions in normal tissue function and the regenerative 
potential with advanced age are most likely caused by the presence of factors elevated or reduced 
as part of the aging process.  An efficacious therapeutic strategy for older patients will thus 
supplement or knock-down levels of particular molecules identified to be altered with increasing 
age, while not negatively impacting the normal healing process that utilizes these same 
molecules.   
 
Changes in the immune system   
           Aging results in changes to the total number and activity of immune cells, both 
those involved in innate immunity (e.g. monocytes, macrophages, natural killer cells and 
dendritic cells), as well as immune cells involved in adaptive immunity that respond to antigens 
(e.g. B- and T-lymphocytes) [143]. With increasing age, more hematopoietic stem cells become 
granulocytes, macrophages and dendritic cells, than B- and T- lymphocytes, thereby reducing the 
ability to fight infection [144]. In normal wound healing, neutrophils are the first cells to a 
wound site, but with age they become slower to arrive at an infection site, despite the fact their 
production rate remains the same with advancing age [144].  The slowed neutrophil response 
gives rapidly dividing bacteria an undesirable head start in older patients.    
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Macrophages have impaired phagocytosis and reduced cytokine production in response to 
bacteria derived lipopolysaccharide (LPS) [145, 146].  The increased background levels of 
proinflammatory cytokines (IL-6 and TNF-alpha) decrease their sensitivity to stimuli and 
prolong inflammation once initiated [147].  Aged mice (both BALB/c and FVB/N) were found to 
have an enhanced inflammatory response similar to older humans, as measured by cytokine and 
chemokine production or neutrophil infiltration, compared with young mice indicating that mice 
can be use a model for aging studies [148].  In addition, transfer of macrophages from young 
mice to old mice was able to reverse impaired wound healing in aged mice [149-151], 
reinforcing the potential gains from therapies focused on shifting the immune system of older 
patients back to a more youthful state.  The wide ranging effects of senescence and aging on the 
immune system have been previously summarized [117, 144].  Overall, the older person’s altered 
immune system make them more prone to infection, prolonged pathological inflammatory 
responses, slower wound healing and less reactive to vaccination.  These immune system 
deficiencies provide the motivation to develop local delivery systems from biomaterials for 
immunomodulation. Schematic representation of the age-related alteration with age can be found 
in Figure 1.1. 
 
1.1.3 Strategies to Date for Modulating Inflammation During Bone Healing 
Given the essential role of macrophages in the bone repair process, they represent an 
attractive therapeutic target for improving bone repair outcomes especially in compromised bone 
of older individuals. Several strategies for local delivery of cytokines have been developed to 
modulate macrophages phenotype to accelerate wound healing in mice. For example, the effect 
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of local co-delivery of IFN  with IL-4 to macrophage and the influence of each phenotype on 
the peripheral nerve regeneration using polysulfone nerve-bridging tubes filled with agarose 
hydrogel [152].  Another study designed silk films embedded with IFN or IL4 to promote M1 or 
M2a polarization [153]. Similarly, osmotic pump has been used to deliver IL4 to mitigate 
orthopedic implant wear particle-associated inflammation [154]. In addition, the sequential 
delivery of immunomodulatory cytokines, IFN and IL-4, was studied to facilitate the transition 
of M1-to-M2 macrophages and enhance bone vascularization in vivo in subcutaneous mouse 
model using decellularized bone scaffolds with biotin–streptavidin interactions [155]. 
Dexamethasone was delivered as an alternative to cytokines to promote M2 polarization and 
reduces fibrous encapsulation using microdialysis tubing [156].  
Preventing the activity of pro-inflammatory factors that are at elevated levels due to 
aging is an alternate strategy to increase bone healing activity in older patients.  Patients with 
chronic periodontitis received systemic doses of an inhibitor to TNFα and that resulted in 
lowered serum level of inflammatory markers and improved outcomes [157]. Quite different 
results were obtained when this strategy was tested in young mice.  Inhibition of endogenous 
TNF, by either systemic delivery of anti-TNF or local injection of recombinant murine IL10 at 
the fracture site, reduced callus mineralization leading to poor bone bridging across the fracture 
site [121]. In the young animals, local rhTNF treatment was only effective to improve mice 
fracture healing when administered within 24 h of injury when only neutrophils were present 
[158].  This provides evidence that strategies being developed to address the altered physiology 
in older patients should be tested in aged rodent models or run the risk of not showing a positive 
effect. 
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1.1.4 Effect of Statins on Bone Healing and as an Immunomodulatory agent 
There is a well-recognized link between the bone and the immune system and in recent 
years there has been a major effort to identify molecules that can target both bone and immune 
cells [159, 160]. Several molecules that were initially identified and studied in the immune 
system and other applications have been shown to have an essential effect also on bone mineral 
density (BMD) and bone healing, such as nonsteroidal anti-inflammatory drug (NSAID), cyclo-
oxygenase selectivity (COX), aspirin and statins [161-165]. Statins, HMG-CoA reductase 
inhibitors, are common cholesterol-lowering drugs. Simvastatin, which belongs to the statin 
family, is administered in the lactone form, which is a prodrug [166-168]. It is rapidly 
hydrolyzed in its first pass through the liver from the inactive lactone to the hydroxy acid active 
form, which has considerable similarity to the structure of acetyl CoA (Fig. 1.2). 
Literature suggests that statins may have potential novel therapeutic effect for diverse 
conditions, ranging from sepsis and inflammatory diseases to chronic wounds and dementia and 
osteoporosis [169, 170].  Statins have been shown to exhibit pro-reparative properties by 
reducing the release of specific chemokines, cytokines and adhesion molecules, as well as 
modulating T-cell activity. Statins inhibit the transendothelial migration of leukocytes by 
decreasing the expression of adhesion molecules, such as Intercellular Adhesion Molecule 1 
(ICAM-1), lymphocyte function-associated antigen-1 and monocyte chemotactic protein-1 [171, 
172]. Moreover, statins further prevent inflammation by inhibiting chemokine release and Th1-
type chemokine receptors on T cells [173, 174].  
The anti-inflammatory activity of statins results in reduced synovial inflammation and 
cartilage degradation in rabbit experimental osteoarthritis [175]. Studies on the 
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immunomodulatory effects of lovastatin on rats with experimental autoimmune encephalitis 
found a decrease in IFN-γ and IL6, with an increase in the anti-inflammatory cytokine IL10. 
Further studies on neuro-inflammatory disorders found that statins inhibited the expression of 
inducible nitric oxide synthase and proinflammatory cytokines TNF-α and IFN-γ, suggesting 
promise for diseases such as multiple sclerosis [176]. Simvastatin was extensively studied for its 
role as anti-inflammation drug and that by inhibiting the production of multiple cytokines such as 
TNF-α , IL-1, IL6 and IL-17 with induction of regenerative cytokines such as IL10, IL-4 and 
IL-27 [177-181]. In this thesis, Simvastatin was used to modulate inflammatory macrophages 
derived from either mouse or human. More detailed review of simvastatin anti-inflammatory 
effect could be found in chapter 3. 
 
1.1.5 Delivery of Simvastatin in Bone Repair 
Beyond simvastatin’s inhibition of cholesterol synthesis, many observational studies have 
reported a positive effect of oral use simvastatin on fracture risk bone mineral density (BMD) in 
older individuals. Simvastatin use was associated with a significant reduction in the risk of hip 
fracture and other non-spine fracture in older patients [182, 183].  One to five years usage of oral 
simvastatin resulted in a significant increase in BMD, both on the spine and femoral hip, 
specifically in postmenopausal women [164, 184, 185]. These studies provided useful 
information about the relation between simvastatin use and fracture risk and BMD among older 
women. However there are multiple side effects associated with all systemic administered drugs, 
simvastatin side effects includes muscle breakdown, liver problems, allergic reactions, diarrhea, 
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headache, and increased blood sugar levels [186]. Therefore local delivery from a biomaterial 
delivery system would overcome side effects of simvastatin. 
Studies have also shown a promising effect of locally delivered simvastatin beta-hydroxy 
acid on bone formation. For example, 20 ug of beta-hydroxy acid simvastatin was loaded in 
Poly(e-caprolactone) (PCL) spiral scaffolds implanted in rats critical size cranial defects. The 
study showed tissue integration within the implant and mineralized bone restoration with 
simvastatin loaded scaffold compared to control  [187]. Jeon et al. compared sustained release of 
1 ug simvastatin hydroxy acid versus 5 ug intermittent release from PLGA microparticles on the 
young male rat calvarial defect. Histological evaluation, 28 days post-implantation showed 
32.3% increase in bone thickness and a 74.1% greater bone area with intermittent release than 
sustained delivery [188]. 
Simvastatin, pro-drug form, was delivered on titanium threaded screw coated with 
biomimetic calcium phosphate showed greater increase in bone area in ovariectomized rat tibia 
fracture [189]. MSCs sheet combined with 0.5 mg simvastatin were locally delivered from 
calcium sulfate (CS) to osteotomy model in rat tibia and resulted in more callus formation 
around the fracture site at 2 weeks, and complete bone union at 8 weeks[190] . Skoglund et al. 
compared systemic subcutaneous injections of 20 mg/day simvastatin or 0.1 mg/kg simvastatin 
directly delivered to mouse femur fracture from an osmotic mini-pump. Local delivery of low 
dose of simvastatin showed better improvement of biomechanical parameters and bone 
formation [191]. Alpha-tricalcium phosphate particles loaded with multiple dose of simvastatin 
delivered locally on adult rat calvarias defect was tested for its osteogenic and inflammatory 
effect. High dose, 0.5 mg, of simvastatin caused more inflammation, while lower, 0.1 mg, dose 
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suppressed inflammation, induced significantly higher bone volumes than the higher dose. 
Simvastatin treatment is dose dependent, too high dose of simvastatin could have negative effect 
on bone formation as well as inflammation [192-194]. Therefore, systemic or local 
administration of high doses of simvastatin might block new bone formation due to accumulation 
of excessive dose on systemic and cellular level.  
 
1.1.6 Calcium Phosphate Delivery Systems Advantages over Polymers 
Calcium phosphates are widely used as synthetic bone grafts providing several 
advantages such as their osteoconductivity, biocompatibility and injectability [195, 196]. 
Moreover, their intrinsic porosity allow for the incorporation of drugs and active biomolecules in 
the coatings providing highly localized delivery of the drug to the targeted site of injury [197]. 
Unlike biodegradable polymer drug delivery systems, bCaP can provide a safe environment for 
the cells with no harmful acidic byproducts seen with some polymer degradation and dissolution 
processes. The byproduct from polymer use may cause a release an acid product that catalyzes 
further degradation providing uncontrolled released of drug that could negatively impact the 
wound microenvironment [198]. We have seen first-hand, in our own in vitro testing, the 
benefits of using novel bCaP coatings on biomaterial as barrier layer for delayed and sequential 
delivery of bioactive molecular to macrophages.   
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1.1.7 Sequential Delivery Systems.  
Multiple strategies of biomaterial drug delivery systems are being developed to provide 
multiple factors delivery mimicking the natural biological tissue regeneration process [199].  
These strategies focused on biomaterials use for multiple regeneration therapeutics such as 
wound healing/infection, bone, cartilage, muscle, teeth and cancer, and have shown some 
efficacy both in vitro [200-202], and in vivo [203] . The use of a biomimetic calcium phosphate 
(bCaP) barrier layer with a poly-L-Lysine (PLLys) and poly-L-Glutamic acid (PLGlut) PEM 
successfully provided pure sequential delivery of two factors to osteoprogenitors in vitro and in 
vivo[204, 205] .   
Several materials have been used to locally modulate bone healing with simvastatin in 
combination with hormones and growth factors. For example; the sequential delivery of PDGF 
and simvastatin were locally delivered from a double-walled PDLLA-PLGA microspheres on rat 
maxillary molars [206]. However, this study was limited in terms of providing information about 
the effect of SIMV combined with another factor on older compromised bone. The combined 
effects of simvastatin and FGF-2 were investigated in vitro on the proliferation and 
differentiation of MC3T3-E1 [207]. Cellulose acetate microspheres were also used in vitro for 
alternating delivery of simvastatin hydroxyacid and PTH [208]. These studies used a young cell 
line which failed to predict the effect of SIMV on primary older cells. Furthermore, these 
approaches were limited by the co-delivery profile provided to the cells and the lack of timely-
control over the factors being delivered. Therefore, there is a need for delivery system offer 
control over the sequence of delivery when modulating inflammatory macrophages for better 
healing outcome. 
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1.1.8 Importance of Controlling the Timing of Immunomodulatory Therapies: 
Inflammatory response, the first stage of healing after tissue injury, is one of the requisite 
phases for successful healing. Blocking the initial inflammatory response can disrupt the delicate 
balance between macrophage subsets and may result in negative outcome.  It is proven that the 
administration of nonsteroidal anti-inflammatory drugs such as cyclooxygenase-1 (COX-1 or 2) 
early times after injury impairs overall healing outcomes as well as osteointegration of dental 
implant [209, 210]. Overall, mounting evidence supports that timely-controlled inflammation is 
required for bone healing. During prolonged inflammation, the continuous infiltration of M1 
macrophages are detrimental to the overall healing process. In fact, prolonged local or systemic 
delivery of M1-polarizing agents, 7 days starting at the time of fracture, compromised normal 
healing in adult rats [211, 212]. On the other hand, the early injection of M2a or M2c 
macrophages directly after in to a mouse wound injury inhibited healing [213].   
 
1.1.9 Gap in Knowledge.  
Bone regeneration and repair is markedly reduced in older patients. Previously, most 
bone regeneration strategies focused on healing younger bone, however these strategy is not as 
effective for treating the injuries of aged patients.  A strategy to address repair of bone injuries in 
older patients must take into consideration the age-related loss of bone quality and inflammaging 
and alterations relative to young cell behavior. Furthermore, most studies to date focused on 
addressing one single cell type or modulating one single molecule within a tissue which is not an 
effective strategy to overcome complex, multifactorial aging effects. The use of high doses of a 
single osteoinductive molecule to accomplish bone repair in older patients and animals is not the 
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best strategy to overcome the reduced healing capacity because it leads to unwanted side effects 
such as an inflammatory response to the growth factor or off-target effects. Local delivery of 
multiple therapeutic molecules that can address the many types of physiological alterations with 
age will offer the best means of accomplishing robust bone regeneration in older patients.  
Therapeutic approaches of the future should be tailored to the older patient’s bone structure, 
physiology and resolve the impaired immunity, enhanced inflammation, and reduced number and 
osteogenic differentiation potential of MSCs associated with the presence of senescent cells to 
expedite bone healing in the elderly. This dissertation research therefore focused on the design of 
a biomaterials drug delivery system that may be used one day to improve bone regeneration 
outcomes. The delivery system is based on a thin layer of biomimetic calcium phosphate: bone-
like apatite with unique delivery profile that allows for stepwise sequential delivery to 
macrophages. 
 
1.2 Hypothesis  
The overarching hypothesis is that sequential, localized delivery of anti-inflammatory/osteogenic 
simvastatin will modulate macrophage transitions and improve osteogenesis. 
 
1.3 Specific Aims 
There is an age-related alteration in macrophage response after injury that prevents 
wound healing initiation and resolution [124]. The long-term goal of our research is to enhance 
older bone regeneration by modulating the innate immune system via local sequential delivery of 
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immunomodulatory cytokines or delayed-localized delivery of anti-inflammatory molecules 
from novel biomaterial coating that can be applied to commercially available bone graft 
substitutes.  
AIM #1: Develop a delivery system for sequential or delayed delivery of 
biomolecules to osteoprogenitors or macrophages using a biomimetic calcium phosphate 
(bCaP) coating. Sub-Hypothesis: If bCaP serves as barrier layer to delay access to a cytotoxic 
compound, antimycin A, then cells (osteoprogenitors or macrophages) should show a delayed 
cell death rather than immediate cell death.  
• 1A: Demonstrate delayed access of RAW264.7 macrophage to cytotoxic antimycin-A 
(AntiA) covered with a bCaP coating. Cells cultured directly on the bCaP coated disks and 
viability will be measured with LIVE staining over time (from 4 hr to 5 days). The Kuhn lab 
previously demonstrated that incorporation of bCaP-PEM was used for sequential delivery of 
two factors to osteoprogenitors. Here we tested the ability of the bCaP-PEM to sequential 
deliver factors to macrophages and studied the differences between using bCaP-PEM as 
compared to bCaP coating. 
• 1B: Visualize the change in bCaP coating integrity as a function of incubation time with 
macrophages by scanning electron microscopy (SEM) imaging to discover the mechanism of 
cell access to the compound covered by a bCaP coating.  
AIM #2: Determine if the sequential delivery of IFN followed by Simvastatin from 
bCaP can modulate macrophage phenotype.  Sub-Hypothesis: If bCaP sequentially delivers 
M1 stimulating IFN followed by M2 stimulating SIMV, then macrophage phenotype should 
show a transition from M1 to M2 over time as measured by gene expression.  
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 2A: Determine the effect of the biomaterial bCaP coating itself on M1 to M2 of THP-1 cells. 
 2B: The M1/M2 transition of the young THP-1 human monocyte cell line will be modulated 
by the sequential delivery of IFN followed by SIMV from bCaP.  
 2C: The M1/M2 transition of the old mouse primary bone marrow macrophages in vitro and 
in vivo was modulated by the sequential delivery of IFN followed by SIMV from bCaP.  
AIM #3: Determine if delayed local delivery of Simvastatin from bCaP can improve 
in vitro osteogenesis. Sub-Hypothesis: If pro-inflammatory cytokines in older cells negatively 
impact osteogenic differentiation, then delivery of anti-inflammatory SIMV, after the pro-
inflammatory phase, will modulate cytokines produced by osteoprogenitors and increase 
osteogenesis.  
 3A: The optimal timing for delivery of beta-hydroxy acid SIMV to increase osteogenesis of 
osteoprogenitor cells from older human was investigated as measured by cytokine production 
and differentiation.  In vitro studies using osteoprogenitors obtained from older human bone 
chips were conducted to determine the effective delayed access dose.  
 3B: Demonstrated delayed delivery of SIMV from bCaP modulates cytokine production and 
increases differentiation of osteoprogenitors from older human bone chip. 
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Figure 1.1: Illustration of age-related alterations that have an effect on reducing bone cell 
contributions to the healing process and impact on overall bone structure with advanced age. 
(Source: modified from [214]). 
 
 
Figure 1.2: Simvastatin structure. (A) Simvastatin in prodrug structure, (B) open ring beta 
hydroxy acid form of simvastatin .  
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Chapter 2  
A bCaP Delivery System for Sequential Delivery of Biomolecules to Macrophages 
and Osteoprogenitors  
2.1 Introduction 
Highly localized, sequential delivery of multiple factors is needed to trigger multiple 
phases of tissue regeneration and to avoid conflicting messages to progenitor stem cells. A 
sequential, cell-mediated delivery system was recently developed in our laboratory for the 
delivery of  two different bioactive factors using a biomimetic calcium phosphate (bCaP) barrier 
layer and a poly-L-Lysine/poly-L-Glutamic acid polyelectrolyte multilayer (PEM) film [204]. 
The study proved that bCaP-PEM could sequentially deliver two factors in vitro to 
osteoprogenitor cells with 3 days gap between the delivery of the two factors. It was also shown 
that the delivery of the factors was based on the cell-interaction with the materials and not based 
on the diffusion of the factors out.  However, the possibility of bCaP-PEM to provide sequential 
delivery to other cell types and the tunability of delivery kinetics were unknown.  
It is critical for new drug delivery systems to offer specific tunability and customize the 
delivery profile to best match the cellular needs around the implant to achieve successful tissue 
regeneration. For example, during bone fracture healing, sequential and overlapping stages of 
regeneration can be distinguished during the healing process [215]. During the early healing 
phases (hematoma formation and inflammation), the skeletal and immune system are closely 
interacting through common cell precursors and molecular mediators [216, 217]. Although the 
whole cascade of healing is complex, it is reported that macrophages are present throughout all 
bone healing phases [218, 219]. They are part of the acute phase response triggered by tissue 
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injury and thus represent one of the earliest cells migrating to the site of injury [9, 220]. Given 
the importance of macrophages impact on the healing process, targeting both osteoprogenitors 
and macrophages with a multiple drug delivery approach is a necessity for successful bone repair 
outcomes. 
The natural processes of tissue development or tissue repair involve the sequential 
synthesis, secretion, and assembly of different matrix components, growth factors, and other 
proteins to guide cell process. There is a clear positive effect from delivering two factors to 
enhance tissue repair over delivering one factor [201, 221]. Several scholars examined the 
synergic effect of local delivery of two growth factors on bone healing especially bone 
morphogenetic proteins (BMPs) combined with other growth factors. For example, a blend of 
BMP-7 with insulin-like growth factor-I (IGF-I) [222], BMP-7 with BMP-2 [223-227], BMP-2  
with IGF-1 [228-230], BMP-2 with Cobalt ions [231], as well as BMP-2 with fibroblast growth 
factor (FGF-2) [205, 232], were all examined and found to achieve better bone healing 
outcomes. Another strategy was developed to promote dentoalveolar regeneration by the 
combined delivery of PDGF-Simvastatin [206]. 
Combinations of growth factors that aid different steps of regeneration are thus 
anticipated to synergistically enhance tissue regeneration. Several different types of delivery 
systems for multiple growth factors have been developed as potential therapeutics for wound 
healing/infection, bone, cartilage, muscle, teeth, and cancer, and have shown some efficacy in 
vitro [200, 201, 203, 233]. The sequential delivery of immunomodulatory cytokines was also 
used to facilitate the transition of macrophage phenotypes and enhance vascularization [155]. 
The co-delivery profile in most of these delivery systems due to uncontrolled diffusion through 
the biomaterial resulted in bad healing outcomes [155].  The drawback of the previous systems 
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motivated this work to offer highly localized delivery targeting both osteoprogenitors and 
macrophages using biomimetic calcium phosphate (bCaP) to avoid off target dosing or 
prolonged exposure to the biomolecule. 
Calcium phosphate coatings have a great potential as a carrier for a drug in orthopedics as 
well as in maxillofacial surgery due to their biocompatibility, osteoconductivity, and easy 
preparation. bCaP coatings techniques were first developed in 1990 by Kokubo and his 
colleagues [234]. bCaP can be deposited by the immersing of a substrate or scaffold in a 
supersaturated solution of CaP under physiological conditions of temperature (37°C) and pH 
(7.4) to nucleate bone-like carbonated apatite. The method has been improved and refined by 
several scholars [235-239]. Recently a biomimetic calcium phosphate bone substitute has been 
developed for local delivery of biomolecules in sustained slow release of the drugs to the site of 
injury [240-252]. 
This chapter examined the use of a thin layer of bCaP coating to provide sequential 
delivery of two factors: one factor above and one factor below the thin bCaP layer to orchestrate 
reparative activities of both macrophages and osteoprogenitors. The tunability of the bCaP-PEM 
system [204] was also investigated in this chapter by removing the PEM film and using one or 
two bCaP layers.  The bCaP layer was altered by increasing time in the simulated body fluid 
solutions used to produce the coating [253, 254]. In addition, because the 
monocytes/macrophages are one of the first cell-types that would interact with the coating [9, 
220], cell culture studies with murine-derived RAW 264.7 macrophage or MC3T3-E1 
osteoprogenitor were conducted to best mimic the natural cell combination around the bone 
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implant. It was hypothesized that removing the PEM film leaving bCaP only or increasing bCaP 
thickness would result in sequential delivery of multiple factors to macrophages. 
This chapter reports the in vitro assessment of the sequential delivery of two factors with 
opposing action (proliferation (FGF-2) or cytotoxic (AntiA)) delivered either from bCaP or 
bCaP-PEM coatings with alternations made to the system by removing the PEM portion or 
varying the bCaP thickness. This study showed that the delivery kinetics from bCaP-PEM can be 
tuned by removing the PEM layer or modulating bCaP thickness. In addition, changes in factor 
delivery kinetics resulting from changing the cell type cultured on the coating. The macrophages 
(RAW 264.7) can dissolve the bCaP crystal to access the embedded factor while the 
osteoprogenitors (MC3T3-E1) made their way through the cracks in the crystal junction to 
access the embedded factor. Variety of cell type should be considered when designing cell 
mediated growth factor delivery systems.  
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2.2 Materials and Methods 
2.2.1 Material Fabrication 
2.2.2.1: bCaP application 
The bCaP deposition procedure followed previously reported method [204]. Briefly, ultra 
violet light-sterilized sandblasted tissue culture polystyrene disks (TCPsb) (NUNC, Rochester, 
NY) 22 mm in diameter were coated with bCaP mineral crystals via extended immersion in 
SBFx5 solutions [238, 253, 255]. bCaP was formed by immersion of TCPsb disks in solution-A  
for 24 hours at 37 C followed by dehydration with series of graded alcohol solutions.  The dried 
disks were then immersed in a second solution (Solution-B) for another 24 hours at 50 C also 
followed by a dehydration step. Solutions A and B salts concentrations are summarized in Table 
2.1. To alter the bCaP coating thickness, the time of incubation in solution B was varied from 24 
hr to 48 hr and replaced with fresh solution every 24 hr. All SBFx5 solution reagents were used 
as received from Sigma-Aldrich.  
 
2.2.2.2: PEM bilayer coating 
Layer-by-layer PEM was applied by automated alternate dipping in poly-glutamic and 
poly-lysine solutions with saline rinses between following previously reported method [204]. 
Briefly, TCPsb disks coated with bCaP were held vertically in a custom 3-D printed sample 
holder and automatically dipped into PEM solutions and saline rinses using a histology staining 
machine (Varistain 24-4, Thermo Shandon, Loughborough, UK). The automatic PEM bi-layer 
process included an adsorption of poly-L-Glutamic acid (PLGlut) (1 mg/ml, Sigma P4761, St. 
Louis, MO) for 10 min followed by 1 min in seven saline rinses. This was followed by 
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adsorption of (poly L Lysine) (PLLys, Sigma P2636, St. Louis, MO) for 10 min followed by 1 
min in seven saline rinses. This cycle was repeated to achieve 30 bilayers of PEM coating on 2-D 
disks.  
 
2.2.2.3: Bioactive Factor Absorption 
Prior to bCaP and PEM coating, 10 μl of 40mM AntiA dissolved in ethanol (213 μg/disk) 
was applied for 10 minutes on one side of the TCPsb disks and then the disk with AntiA was 
rinsed three times with saline. After that, (AntiA adsorption and bCaP and PEM coating) were 
applied, a carrier free recombinant human FGF-2 (R & D Systems, Minneapolis, MN) in saline 
was applied to the coated disks. Disks were incubated for 1 hr in 0.5 ml (375 ng/ml) of FGF-2 
solution to allow binding to the surface and then rinsed three times with saline. Previous studies 
had determined that the final dose of FGF-2 was 120 ng/disk by Enzyme-linked immunosorbent 
assay (ELISA) on the post-binding and rinse solutions [204]. 
 
2.2.2 Characterization 
Cell Culture Assays 
MC3T3-E1 mouse calvarial osteoprogenitor cells (ATCC, Manassas, VA) or 
macrophages RAW 264.7 (ATCC, Manassas, VA) were cultured in Alpha-Minimal Essential 
Medium (α-MEM, No. 12571, Gibco BRL, Invitrogen) supplemented with 10% fetal bovine 
serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin sulfate. The medium was 
refreshed three times a week until cells reached 80% confluency and passages 10–30 were 
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routinely used. For passaging and seeding, MC3T3-E1 cells were removed from the flasks by 
treatment with 0.25% Trypsin-EDTA (Sigma, St. Louis, MO) for 3 minutes. Macrophages were 
gently scraped from the flasks using a sterile cell scraper (Sigma, St. Louis, MO). Cells were 
counted using an automated cell counter (Bio-Rad, TC20) with trypan blue staining prior to cell 
seeding on coated disks. Prior to cell seeding, coated disks were UV sterilized for 10 min on 
each side and then incubated α-MEM medium for 35 minutes in non-treated tissue culture 12-
well plates (Corning Inc., Corning, NY). MC3T3-E1s were seeded at 4 x 10
4
 cells/cm
2
 in culture 
medium while RAW 264.7 and THP-1 cells were seeded at 3 x 10
4
 cells/cm
2
 and incubated at 
37°C and 5% CO2.  
LIVE® staining (Invitrogen Life Technologies, Grand Island, NY) was performed on 
both cells following the manufacturer’s protocol. At various time points after cell seeding, coated 
disks were transferred to a new 12-well plate (Corning Inc., Corning, NY) and washed with 
phosphate buffered saline solution (PBS) to remove non-adherent cells and incubated at room 
temperature for 30 minutes in LIVE® staining reagents. After 30 min of incubation, disks were 
flipped over for imaging at 100X magnification using an inverted microscope (TE300, Nikon) 
equipped with a camera (Diagnostic Instruments), and imaging software (Spot Insight, Nikon).   
Cell density was quantified as average percent fluorescent area via ImageJ software (U. 
S. National Institutes of Health, Bethesda, Maryland, US) as follows.  Image analysis of 3 
images per well with 3 replicates. Average percent fluorescently labelled area of 3 images taken 
per well was determined by standardized thresholding and ImageJ analysis. Percent cell death 
was calculated by subtracting the average percent live stained area of the AntiA group 
normalized by its respective AntiA-negative control from 100%. All experiments were repeated 
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at least three times. The CellTiter-Blue® (CTB) (Promega Corporation, WI, USA) cell viability 
assay was used on bCaP only disks (data are not shown here) for comparison to the live staining 
method.  All experiments were repeated at least three times. Schematic representation of the 
experimental setup and coating method can be found in Figure 2.1. 
 
Evaluation of Cell Access Mechanism:  
Scanning electron microscopy (SEM) (JSM - 5900LV, Jeol USA Inc. Peabody, MA) was 
used to examine the coating before and after incubation in culture medium for 4 hr or 3 days with 
or without cells to determine the coating degradation mechanisms in the presence and absence of 
PEM coatings. Either MC3T3-E1 , RAW 264.7 cells were cultured on disks coated with AntiA-
bCaP-FGF2, or AntiA-bCaP-PEM30-FGF2. LIVE® staining was performed to examine cell 
access kinetics and then cells were removed by incubation in Trypsin-EDTA (Sigma, St. Louis, 
MO).  
For SEM preparation, the trypsin solution was removed, disks were washed three times 
with DI water and dried with a series of ethanol solutions. Disks with PEM coatings were 
critically point dried after ethanol dehydration using (LEICA EM CPD030, Leica Microsystems 
Inc. Buffalo Grove, IL, United States) to preserve the delicate surface structure of PEM film. 
After drying, disks were sputtered coated (vacuum DESK V, Denton Vacuum, LLC, NJ, United 
States) and imaged using SEM (SEM, TM-1000, Hitachi High-Technologies Corporation, 
Tokyo, Japan). SEM analysis was conducted on at least three samples per group. 
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2.2.3 Statistical Analysis 
Statistical significances were determined using Graph Pad Prism software by unpaired t-
tests if only two groups were in the study or by one-way ANOVA with Tukey post-tests for 
multiple comparisons in larger studies with P values > 0.05 being considered statistically 
significant. 
 
2.3 Results 
2.3.1 Characterization of the Coatings bCaP vs. bCaP-PEM 
MC3T3-E1 cell proliferation and viability on bCaP-coating was compared to cell 
cultured on bCaP-PEM30 to examine cell growth on the biomaterial coatings without any 
factors. Calcium phosphate layer (bCaP) enhanced cell proliferation over time compared to bCaP 
plus PEM. A significant decrease in percent LIVE® stained area of MC3T3-E1 cells was 
observed when cells cultured on bCaP-PEM (blue) as compared to cells cultured on bCaP-only 
(Gray) at day 1, 3 and 5 (Fig. 2.2 A, B).  
To change the delivery profile from the bCaP-PEM system, PEM film was removed and 
cells were grown on bCaP coating as compared to cells cultured on bCaP -PEM film.  MC3T3-
E1 cells were either cultured on bCaP(24h) or bCaP (24h)-PEM coating with AntiA embedded 
beneath the bCaP coating and FGF2 on top of bCaP coating. MC3T3-E1s initially proliferated 
and then abruptly accessed the embedded AntiA on day 3 on AntiA-bCaP-PEM-FGF2 and then 
recovered (Fig 2.3 A, B). However, on bCaP(24h) coating without PEM, the AntiA was accessed 
by the cells on day 2 with less cell recovery over the time points studied compared to bCaP-PEM 
coating (Fig 2.3 C, D). 
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 To further extend the timing of access between the two factors delivered to 
osteoprogenitors, bCaP barrier layer thickness was increased. Altering bCaP layer thickness was 
successfully achieved by changing the incubation time in solution B. Depositing thicker bCap 
layer resulted in no further delay in cells the access to the embedded factor. bCaP(48h) layer 
without PEM resulted in a more gradual access to the cytotoxic AntiA than bCaP(24h) but cell 
access was still detected on day 2 as measured by significant decrease in LIVE® staining on day 
2 and the remaining time points in the study (Fig 2.3 E, F). 
Studies with RAW 264.7 macrophages as compared to MC3T3-E1 mouse calvarial 
osteoprogenitors were conducted to investigate the possibility of altering the delivery kinetics of 
the factors by changing the cell type.  Changing cell type to macrophages altered delivery kinetic 
of AntiA. RAW264.7 cells immediately accessed the embedded AntiA on disks coated with 
AntiA-bCaP-PEM-FGF2 observed by the significant decrease in LIVE® at 4 hrs and throughout 
the duration of the study (Fig. 2.4 A, B).  Removing PEM film resulted in 2 days delay access by 
the macrophages (RAW 264.7) to the embedded AntiA on bCaP without PEM (Fig. 2.4 C, D).  
 
2.3.2 Cell Access Mechanisms by SEM Imaging  
SEM imaging was used before and after the cell culture on disks coated with bCaP and 
bCaP-PEM to investigate the mechanism followed by both cells type to access the embedded 
factor. SEM revealed that the incubation of bCaP-PEM coated disks in culture medium alone 
without cells resulted in changes in the surface structure of the cracks present in the coating 
indicating that the dissolution process opened the crystal junction between bCaP crystal (wider 
cracks were noticed) to facilitate cell access (Fig 2.5 A and B). The cracks were sharper after 
42 
 
 
MC3T3-E1 cultured on bCaP-PEM coated disk and wider when RAW cells cultured on bCaP-
PEM coated disks (Fig 2.6 C). RAW cells did not have noticeable effect on the surface coating at 
4hrs but changed the cracks structure on day3 (Fig 2.5 D).  
SEM showed wider cracks between the crystal clusters of bCaP coating after the bCaP 
coated disks was incubated in cell culture medium (Fig 2.6 A, B). SEM revealed that RAW cells 
dissolved bCaP and created micro-openings in the bCaP coating to get access to the embedded 
AntiA on bCaP coating (Fig 2.6 D). SEM showed more cracks between the crystal junctions 
when a thicker layer of bCaP (48 hr long deposition time) was deposited and these cracks were 
even wider after MC3T3-E1 was cultured on the surface (Fig 2.7). 
 
2.4 Discussion 
Local delivery of single factor or combination of two factors using biomaterials has 
significantly progressed over the years reviewed by Kangwon Lee et al [199]. An ideal local 
delivery system should mimic the normal physiologic environment by controlling the timing and 
concentration of factors to be delivered. The ability of bCaP-PEM system [204] to tune factors 
delivery kinetic was investigated in this study for possible use of the system with multiple 
applications given the tunablity of the delivery offered by this study. The system ability to tune 
factor delivery was tested by the removal of PEM film or changing bCaP thickness.  
PEM film caused decrease in cell viability as compared to cells grown on bCaP coatings 
without the PEM film. The reduced cells viability with bCaP-PEM is due to the effect of poly-L-
Lysine within the coating. The PLLys is known to have slightly cytotoxic effect with time and 
concentration dependent assisted with MTT cytotoxicity evaluation assay [256, 257]. An 
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alternative strategy to delay cell access to embedded factor is by removing PEM layers and 
increase bCaP coating thickness. 
bCaP coating thickness was either decreased or increased by changing the incubation 
time in solution B of the SBF during bCaP deposition.  Increasing or decreasing the incubation 
time resulted in increase or decrease in the bCaP coating thickness [238, 239, 255]. Depositing a 
thicker bCaP(48h) layer did not change delivery kinetic observed by MC3T3-E-1. It is believed 
that increasing bCaP thickness have no effect on the access process of the cells as cells ability to 
penetrate the coating and access the embedded factors as compared to a thinner bCaP layer. It 
also believed that bCaP layer has nano-porous structure making the penetration of the cells 
through the pores easier to achieve with a thinner layer of bCaP [258-260].  
Given the wide variety of cell types interacting with the biomaterial implanted in the 
body; an ideal biomaterial delivery system should have the ability to coordinate with the innate 
immune response. Macrophages are essential cells contribute in early phase of the regeneration 
process of any healing process. Macrophages are one of the very first cells interacting with the 
implanted materials [261] and have essential role in regulating tissue repair and tissue response 
to biomaterials [262-264]. Macrophages cell-type is known to have the ability of fast degradation 
or resorption of the coated material. RAW 264.7, a macrophages cell line, in particular have the 
ability to degrade non-cross-linked polyelectrolyte multilayer films [265].  In this study RAW 
264.7 cells showed immediate no delay access to the embedded AntiA when cultured on bCaP-
PEM and 2 days delay when cultured on bCaP without PEM. This change in delivery profile 
could be due (a) enhanced ability of macrophages to degrade the coating over osteoprogenitors; 
and (b) to the changes in bCaP surface morphology when covered with PEM. Previous study 
showed that bCaP crystallinity was reduced when bCaP coating covered with PEM film [204] 
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which enhanced and expedited the degradation process by the RAW cells.  Varying cell type 
profoundly affected the surface coating and kinetics of delivery making this system valuable for 
applications to target specific cell type behavior.  
For better assessment of cells mechanism of access to the embedded AntiA; SEM 
imaging was performed on coated disk before and after cell culture. Cells cultured on bCaP-PEM 
coated disk did not impact the surface coatings with both cell types. The dissolution process 
opened the crystal junction especially when bCaP coating without PEM was used.  It was also 
noticed that the incubation in medium alone opened the cracks between the bCaP crystal 
junctions. Since incubation in medium made the cracks wider; it is believed that MC3T3-E1 
were able to penetrate their processes through the wider cracks to access AntiA on day 2. RAW 
cells followed different approach by dissolving the bCaP coatings on day 3 of cell cultured on 
AntiA-bCaP . Macrophages have ability to produce factors that can dissolve the bCaP coating. 
RAW cells not only able to dissolve carbonate substrate, but also change in cells morphology 
was reported in response to the culture surface [266].   
 
2.5 Conclusions 
These studies proved that the drug delivery from bCaP-PEM system is governed by the 
interaction of the cells with the mineral-poly amino acid layered structure rather than by typical 
drug diffusion. Delivery kinetics could be tuned by removing PEM layers to best serve delayed 
delivery to macrophages. Removing PEM coating allowed earlier access by osteoprogenitor cells 
indicating PEM is an important component of the system when targeting this type of cells. 
Varying cell type profoundly affected the surface coating and tuned kinetics of delivery due to (i) 
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the enhanced ability of macrophages over osteoprogenitors to degrade the coating, and (ii) 
reduced bCaP crystallinity after the PEM coating procedure which caused expedited access to 
the second factor by RAW cells. Future work will be focused on the use of the bCaP system to 
modulate the innate immune cells with different biomolecular targeting both osteoprogenitor and 
macrophages behavior. 
 
Table 2.1 Nominal chemical composition of Solutions A and B in mM.   
Inorganic Salt Solution A Solution B Reagent Chemical 
Na+ 733.5 733.5 Sodium chloride (NaCl) 
Mg
2
+ 7.5 1.5 Magnesium Chloride, Hexahydrate 
(MgCl2  6H2O) 
Ca
2
+ 12.5 12.5 Calcium chloride dihydrate.  
(CaCl2  2H2O) 
Cl- 720 720  
HPO4
2
- 5 5 Sodium Hydrogen Phosphate 
(Na2HPO4  2H2O) 
HCO3- 21 10 Sodium Hydrogen Carbonate 
(NaHCO3) 
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Figure 2.1. Schematic representation of disks coatings preparation and analysis. 
 
Figure 2.2: Osteoprogenitors cultured on bCaP coating or bCaP-PEM without any drug. (A) 
Percent of LIVE® stained area of MC3T3-E1s on bCaP (24h) (-A/-F) vs. bCaP (24h)-PEM (-A/-
F) showing better cell growth and viability on bCaP coating as compared to the combination of 
bCaP-PEM. (B) Fluorescent LIVE® stained images of MC3T3-E1 cells on bCaP (24h) and bCaP 
(24h)-PEM. 
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Figure 2.3: (A) % LIVE® stained area of MC3T3-E1s on bCaP24hr -FGF2 (-A/+F) vs .AntiA-
bCaP24hr -FGF2 (+A/+F). (B) Fluorescent image of LIVE® staining of MC3T3-E1s on 
bCaP24hr -FGF2 (-A/+F) and on AntiA-bCaP24hr -FGF2  (+A/+F). (C) % LIVE® stained area 
of MC3T3-E1s on bCaP48hr -FGF2 (-A/+F) vs AntiA-bCaP48hr -FGF2 (+A/+F), D) fluorescent 
image of LIVE® stain of MC3T3-E1s on bCaP48hr -FGF2 (-A/+F) and on AntiA-bCaP48hr -
FGF2  (+A/+F) ,  (**** P < 0.001).  Scale bar = 100 μm.  
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Figure 2.4: Tuning delivery kinetics by changing cell type and removing PEM coating (A) 
Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (-A/+F) as 
compared to cells cultured on AntiA-bCaP-PEM30-FGF2 (+A/+F) showing RAW264.7 cells 
immediately accessing the embedded AntiA on 4hrs of culture (* P < 0.05, ** P < 0.01, *** P < 
0.001). (B) Fluorescent LIVE stained images of cells cultured on bCaP-PEM30-FGF2 (-A/+F) as 
compared to cells cultured on AntiA-bCaP-PEM30-FGF2 (+A/+F) at 4 h, 1, 2, and 3 days of 
culture. (C) Percent  LIVE® stained area of RAW cells on  bCaP coating showing access to 
AntiA on day 3 of culture ( ** P < 0.01, **** P < 0.001), ). (D) Fluorescent LIVE stained 
images of cells cultured on bCaP-FGF2 (-A/+F) as compared to cells cultured on AntiA-bCaP- 
FGF2 (+A/+F) at 4 h, 1, 2, and 3 days of culture. Scale bar = 100 μm.  
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Figure 2.5:  Scanning electron microscopy of bCaP with AntiA. (Column A) SEM of AntiA-
bCap(24)-PEM before cell culture. (Column B) SEM of AntiA-bCap(24)-PEM coated disk and 
incubated in cell medium for 4hrs and 3 days without cells. (Column C) 4hrs and Day3 LIVE 
staining +A/+F AntiA-bCaP(24)-PEM-MC3T3-E1. (Column D) 4hrs and Day-3 LIVE staining 
+A/+F AntiA-bCaP(24)-PEM-RAW. 
 
 
Figure 2.6:  SEM imaging of AntiA-bCaP coated disks (Column A) SEM of AntiA-bCap(24) 
before cell culture. (Column B) SEM of AntiA-bCap(24) coated disk and incubated in cell 
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medium for 4hrs and 3 days without cells. (Column C) 4hrs and Day3 LIVE staining +A/+F 
AntiA-bCaP(24)-MC3T3-E1. (Column D) 4hrs and Day-3 LIVE staining +A/+F AntiA-
bCaP(24)- RAW. 
 
 
Figure 2.7 :  SEM images of bCaP (48hrs). (Column A) bCap(48) before cell culture with AntiA 
and without AntiA. (Column B) 4hrs and Day3 LIVE staining –A/+F-bCaP(48)-MC3T3-E1, 
bCa(48) coating after 4hrs and 3 days of cell culture –A/+F and correspondent SEM imaging. 
(Column C) 4hrs and Day3 LIVE staining +A/+F-bCaP(48)-MC3T3-E1 and SEM images of the 
coating after 4hrs and 3 days of cell culture. 
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Chapter 3  
Controlled M1-to-M2 Transition of Aged Macrophages from Calcium Phosphate 
Coatings  
3.1 Introduction 
Macrophages are present in nearly all tissues and are critical for tissue remodeling, 
homeostasis, and regeneration. Most tissues contain a population of resident macrophages that 
are able to dynamically adapt to changes in their microenvironment in order to orchestrate 
critical tissue-specific functions.  After a bone injury, macrophages are among the first cells 
recruited from the bone marrow and peripheral blood to the site of injury, where they coexist 
with resident macrophages within the bone injury site [218]. Depending on the stage of healing 
at the injured site, macrophages become polarized toward an appropriate activation pathway that 
helps to regulate all phases of the healing process. First, macrophages exhibit a pro-inflammatory 
phenotype (commonly referred to as M1) [25]. M1 macrophages are critical for the initiation of 
angiogenesis and osteogenesis [26]. At later stages of healing, M1 macrophages transition to a 
pro-reparative phenotype (commonly referred to as M2) to guide the repair process to 
completion [26]. It is now known that M2 macrophages can be further subdivided into a series of 
distinct phenotypes, each with diverse functions ranging from tissue deposition to tissue 
remodeling [27]. Injuries with poor healing outcomes are associated with a stalled M1-to-M2 
transition [267, 268].  Given the sequential and synergistic roles of M1 and M2 macrophages in 
the healing process, it has been proposed that biomaterial strategies that sequentially promote M1 
and M2 activation will enhance healing compared to promotion of either phenotype alone or 
concurrent promotion of both types [26, 155, 269].  
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Many patients requiring bone repair treatments are older with chronic low levels of 
inflammation [117].  A few studies have examined the behavior of macrophages obtained from 
older mice and humans and seen an age-related impairment in macrophage polarization, cytokine 
production, phagocytic ability and have linked this to the impaired bone healing seen in older 
patients [122, 270, 271]. Age-related alterations in macrophage function and response to stimuli 
have been reported in old mouse bone marrow derived macrophages [125, 146, 272-274], as well 
as in human macrophages derived from peripheral blood monocytes taken from older patients 
over 65 years of age [275]. In general, macrophages from older humans and animals tend to 
secrete higher baseline levels of pro-inflammatory (M1) cytokines (e.g. IL6 and TNF), and 
respond more slowly to inflammatory stimuli as compared to macrophages from young humans 
and animals [276]. Decreased production of pro-reparative (M2) cytokines has been observed in 
macrophages from old mice [270]. There is also an increase in macrophage accumulation in 
dermal, adipose, thyroid and liver tissue in older humans and animals [271, 277-279].  In mice, it 
was demonstrated that transplanting bone marrow that contains the hematopoetic precursors for 
macrophages from 4-week-old young mice into 12-month-old adult mice improved fracture 
healing [280]. In addition, impaired cutaneous wound healing in aged mice was reversed when 
macrophages from young mice were transferred to aged mice [281]. Thus, a biomaterials delivery 
system with appropriately timed delivery of stimuli that can restore youthful macrophage 
polarization of endogenous macrophages could be a promising approach to enhance bone and 
tissue healing in the older population, but must consider the alterations to the macrophages 
present in the elderly tissue environment. 
Several strategies for local delivery of molecules to modulate macrophage phenotype in 
young mice have been developed to accelerate tissue repair. M1 macrophages are usually 
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activated by interferon gamma (IFNγ) and/or lipopolysaccharide (LPS), while M2 macrophages 
are activated by interleukins IL-4, IL-13 or IL10 [29, 31], although it is likely that polarization 
stimuli in vivo are more complex and multifaceted. In a murine subcutaneous implantation 
model, the release of IFNγ enhanced vascularization relative to controls, but the dual delivery 
with IL-4 had no effect [155]. The lack of effect was attributed to the overlapping IFNγ and IL4 
release profiles at the early phases, which caused simultaneous, not constructive, M1 and M2 
activation. Indeed, too early of an increase of M2 macrophages can be detrimental as shown by 
impaired wound healing from administration of M2 macrophages at early times after injury 
[213], although this finding may be context-dependent [271]. Thus, a major goal of the present 
study was to design a biomaterial drug delivery system that sequentially delivers M1- and M2-
promoting stimuli in distinct phases and to test the strategy in macrophage sfrom old mice.   
In the present study, the applicability of a biomimetic calcium phosphate (bCaP) coating 
to serve as a highly localized delivery system to guide macrophage phenotype transitions was 
tested. The effect of in vitro sequential delivery of M1-stimulating IFN followed by the anti-
inflammatory, M2-promoting simvastatin (SIMV) [177, 282-288] by bCaP was studied.  Both 
human macrophages (THP-1 cell line), as well as primary mouse-bone marrow derived 
macrophages were tested.  Macrophages were obtained from very old mice, 25-26 months old, 
that correlates to >85 human years [289].  The overall goal of the study was to test the hypothesis 
that the sequential delivery of IFN followed by SIMV from bCaP can sequentially polarize both 
young and aged macrophages, in vitro, from M1 to M2.  
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3.2. Materials and Methods 
3.2.1. Application of bCaP coating with or without macrophage stimulating molecules 
Simvastatin, (PHR1438, Sigma Aldrich), the M2-promoting molecule, was adsorbed 
directly on ultra violet light-sterilized, 22 mm, by placing 10 ul of ethanol containing 0, 2 or 10 
g SIMV on the side of the TCPsb disks to be cell-seeded and allowing it to dry for 10 min. A 
coating of bCaP was deposited to cover the SIMV or vehicle following a previously reported 
method [204].  Briefly, the disks were immersed in a 5x concentrated simulated body fluid 
solution in a two-step process leading to a crystalline, bone-like apatite coating [238, 253, 255]. 
After bCaP application, 0, 250 or 500 ng of the M1 stimulating molecule IFN (Cat#300-02, 
Peprotech Inc, NJ) in 0.5 ml PBS was adsorbed for one-hour on the outer surface of the bCaP 
coated disks and then rinsed with PBS.  Disks were placed in 12 well non-treated tissue culture 
plastic cell culture dishes (Corning, USA, Cat# 351143) for the studies.  Cells were also cultured 
directly on the non-treated polystyrene as a control for comparison to bCaP coated disks. 
In the studies that determined the kinetics of macrophage access to a factor embedded 
below the bCaP layer, a cytotoxic dose of antimycin A (AntiA, Cat# A8674, Sigma, St. Louis, 
MO) was pipetted on to the TCPsb, allowed to adsorb and then covered with a layer of bCaP as 
described above.  The dose of 213 μg/disk was applied by placing10 μl of a 40 mM solution in 
ethanol on the side of the TCPsb disks to be cell-seeded, allowed to dry for 10 minutes and then 
rinsed three times with saline prior to bCaP coating.  No SIMV or IFNwere used in the 
experiments with AntiA.   
To determine the binding efficiency of IFN to the bCaP surface, a binding solution of 
250 ng of IFN in 0.5 ml PBS was placed on bCaP coated disks for one hour and then collected 
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for enzyme-linked immunosorbent assay ELISA (PeproTech, Inc., New Jersey, Cat# 900-
TM27).  The disk was then rinsed twice with PBS with the first rinse removed immediately and 
the second one after 30 min. The difference between initial binding solution concentration and 
the concentration after 1 hr adsorption was used to determine the IFN bound on the disks. 100% 
binding efficiency of SIMV and Anti A was assumed based on their poor solubility and inability 
to detect the molecules by standard UV-VIS methods. 
 
3.2.2 Cell culture  
Young human peripheral blood derived macrophages: The monocyte cell line THP-1 
(ATCC
®
 TIB-202™) that is derived from human peripheral blood were used to obtain 
macrophages for the studies.  THP-1 cells were expanded in ultra-low attachment flasks 
(Corning, USA, cat# CLS3814) in RPMI medium (Thermo Fisher Scientific, MA, USA) with 
10% heat inactivated fetal bovine serum (FBS), and 100 U/ml penicillin and 100 μg/ml 
streptomycin sulfate. THP-1 at 0.6 million cells/ml were differentiated to macrophages through 
incubation in 100 mM phorbol-12-myristate 13-acetate (PMA) (Sigma, USA, P8139) for 24 hrs. 
Macrophages were then gently scraped off the ultra-low attachment culture flask and seeded at 1 
x106 cell/ml on bCaP coated disks with or without the drugs/cytokines that had been incubated 
for 30 min in Roswell Park Memorial Institute (RPMI) medium (Thermo Fisher Scientific, MA, 
USA) prior to cell culture. In the SIMV dose determination studies, cells were cultured with 
100ng/ml of both LPS and IFNγ in the medium to provide the M1 stimulation, and then 
refreshed on day 3 with drug free medium to evaluate the M2 effect of simvastatin. 
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Mouse Bone Marrow Derived Macrophages (BMDMs): The preparation of BMDMs 
from adult and old mice followed a previously described method [30]. Briefly, four male 
C57BL/6 mice that were either 6 months (adult) or 25 months old (old) were euthanized using 
CO2 inhalation according to a protocol approved by the Institutional Animal Care Use 
Committee of University of Connecticut Health Center following recommendations of the Panel 
on Euthanasia of the American Veterinary Medical Association. Bone marrow of the dissected 
femurs and tibias were flushed with 5 mL DMEM (Gibco™ Invitrogen, CA, USA). The marrow 
was centrifuged for 5 mins and washed twice with medium and then cultured for five days in 100 
mm non-treated tissue culture dish with 10% heat-inactivated FBS, 20 ng/mL monocyte colony 
stimulating factor (M-CSF) (PeproTech, Inc, NJ, USA, Cat# 300-25) and 100 U/mL penicillin 
and 100 μg/mL streptomycin. The cells were then gently scraped off the dish and re-suspended 
with media and plated at 0.5 x106 cell/ml on bCaP coated disks with or without the 
drugs/cytokines that had been incubated for 30 min in RPMI medium prior to cell culture.  Time 
points for analysis were restricted to day 1 and day 6 due to the difficulty of obtaining more than 
four of the very old mice at a time.  Studies were repeated twice. 
 
3.2.3 Characterization of macrophage phenotype transitions  
Macrophage phenotype characterization: The expression of a panel of genes previously 
identified to be suitable for discriminating M1 and M2 macrophage phenotypes were evaluated 
in these studies (42).  Given the previous time scale of macrophage phenotype transitions in 
response to biomaterials observed in our earlier studies (9), the time points of 1, 3 and 6 days 
were selected for analysis of macrophage phenotype on the bCaP coated disks.  Primer 
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sequences can be found in Table 1. The cells were harvested for gene analysis using TRIzol 
reagent (Invitrogen Life Technologies, CA, USA).  RNA was reverse transcribed into cDNA 
using EcoDry Premix (Oligo dT) (Cat# 639543, Clontech) and thermocycler (BIO-RAD 
Laboratories Inc., CA, USA) followed by Quantitative Polymerase chain reaction (qPCR) using 
iTaq™ universal SYBR® Green supermix kit (BIO-RAD Laboratories Inc., CA, USA) on a 
MyiQTM instrument. Values were normalized to GAPDH using 2−∆𝑐𝑡 method, where ΔCT is the 
result of subtracting [CT gene − CT GAPDH] of control or experimental group.   
Kinetics of macrophage access to the factor below bCaP coating: LIVE® staining 
(Invitrogen Life Technologies, Grand Island, NY), as per the manufacturer’s protocol, was used 
to evaluate THP-1 macrophage access over time to the cytotoxic AntiA adsorbed under the bCaP 
coating.  Cells cultured on the disks were imaged at 100X magnification using an inverted 
microscope (TE300, Nikon) equipped with a camera (Diagnostic Instruments), and imaging 
software (Spot Insight, Nikon).  THP-1 cell density was quantified as average percent fluorescent 
area via ImageJ software (U. S. National Institutes of Health, Bethesda, Maryland, US) as 
follows:  the images were converted to grayscale; threshold to binary images and the percent area 
of LIVE stain were estimated using Image-J software (U. S. National Institutes of Health, 
Bethesda, Maryland, USA). Percent cell viability was calculated by comparing the average 
percent fluorescent area of the AntiA group to its AntiA-free control. ImageJ analysis was 
performed for 3 images per well with 3 wells per each experimental time point. 
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3.2.4 Statistical Analysis 
Statistical analysis performed using unpaired t-tests for two groups or by one-way 
ANOVA (P<0.05) with Tukey post-test for 3 or more groups (using GraphPad Prism). 
 
3.3. Results 
3.3.1 Localized, temporally controlled drug delivery from bCaP coatings 
To understand the timing of macrophage access to drug embedded below the bCaP 
barrier layer, human THP-1-derived macrophages were cultured on bCaP or bCaP-AntiA-coated 
disks and cell viability was quantified. While the macrophages initially proliferated in both 
groups, by day 3 the macrophages began to die on scaffolds coated with bCaP-AntiA, indicating 
that the cells accessed the cytotoxic drug by that time point (Figure 3.1).  With regards to the 
dose of IFN adsorbed on the outer surface of the bCaP, ELISA testing revealed that 96% of the 
IFN placed on the bCaP bound to bCaP coating. The IFN concentration was not measurable in 
the 30 min rinse solution by ELISA. This further confirms the highly localized nature of delivery 
from a bCaP coating as reported earlier (27).   
 
3.3.2 Response of macrophages to bCaP coatings  
As a step towards understanding the effect of the bCaP coating itself without additional 
factors to modulate macrophage behavior, the response of macrophages to this material was 
compared to a control, non-tissue culture-treated polystyrene (PS). Culture of human THP1 
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monocyte-derived macrophages on the bCaP coating resulted in upregulation of all three M1 
markers measured at 1 and 6 days of culture as compared to PS (Figure 3.2 A-C). The M2 
markers were not affected by culture on bCaP compared to PS (Figure 3.2 D and E). 
 
3.3.3 SIMV dose optimization  
To determine the dose of SIMV delivered from bCaP that could influence M2 
polarization, human THP1-derived macrophages were cultured on bCaP-coated disks containing 
2 or 10 g of SIMV in the presence of M1-polarizing stimuli, IFNand LPS, contained in culture 
medium for the first three days.  Interestingly, increasing the dose of SIMV from 2 to 10 g 
caused an increase in expression of the M1 marker CCL1 at days 2 and 3 and in CXCL10 at day 
3. By day 4, however, SIMV caused the expression of all three M1 markers to decrease, 
concomitantly with an increase in expression of the M2 markers CCL17 and CD163 in a dose-
responsive way (Figure 3.3 D and E).  
 
3.3.4 Sequential delivery of IFN followed by SIMV 
To determine if adsorbed IFN delivered from bCaP could promote early polarization to 
the M1 phenotype prior to SIMV-mediated M2 polarization, in the absence of inflammatory 
stimuli in the media, macrophages were cultured on bCaP coatings adsorbed with 0, 250 ng and 
500 ng of IFN with 10 g SIMV embedded within the bCaP coating. Both doses of IFN 
polarized THP-1-derived macrophages to the M1 phenotype at the early time point (1 day), as 
measured by increased expression of CCL1, CXCL10 and CXCL11, compared to the bCaP-SIMV 
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control (Figure 3.4 A-C). Upregulation of CCL1 and CXCL11 was also maintained on day 3. By 
day 6, the expression of all three M1 markers had returned to baseline levels of macrophages 
cultured on bCaP-SIMV without IFN. The expression of the M2 markers increased in all bCaP 
loaded with SIMV, but only at the day 6 time point (Figure 3.4 D and E). The shift from M1, 
stimulated by immediate IFN delivery from bCaP, to M2 phenotype, stimulated by delayed 
SIMV delivery from bCaP, confirmed the ability of bCaP to serve as barrier layer between the 
two factors delivered to macrophages with no overlap between the molecules to be delivered.  
Finally, the optimal doses of IFN (250ng) and SIMV (10g) were tested together and 
compared to the delivery of either molecule delivered alone from bCaP coating. The adsorption 
of IFN (without SIMV in the bCaP coatings) caused upregulation of M1 markers at both the 
early and late time points (Figure 3.5 A-C). However, upregulation of M1 markers was inhibited 
at later time points by the SIMV incorporated into the bCaP coating.  Concurrently, at the later 
time points, there was upregulation of M2 markers by coatings containing SIMV with and 
without IFNγ adsorption (Figure 3.5 D, E), indicating that SIMV is both anti-inflammatory and 
M2-promoting.  
 
3.3.5 Response of primary murine macrophages to the sequential delivery system  
The ability of the sequential delivery system to polarize primary cells was tested in bone 
marrow derived macrophages from both aged (25 months) and adult C57/B16 male mice. As 
hypothesized, the sequential delivery of 250 ng IFNfollowed by 10 g SIMV from bCaP 
resulted in elevation of M1 markers on day 1, as measured by the gene expression of Il1, Nos2 
and Cxcl11, compared to cells cultured on bCaP control with no stimuli (Figure 6 A-C).  The M2 
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markers Ccl17 and Arg1 were elevated on day 6 of culture compared to cells grown on bCaP 
(Figure 3.6 D and E).  
Given reports of age-related alterations to macrophages, the effects of localized delivery 
SIMV by bCaP on M2 polarization of old macrophages were compared to the effects on 
macrophages from adult mice.  In these studies, initial inflammatory conditions were induced by 
LPS and IFNγ included in the media for 3 days and not delivered by the bCaP. The expected 
initial inflammatory response arose from IFNγ and LPS in both young and aged macrophages as 
evidenced by an increase of M1 markers (Il1, Nos2 and Cxcl1).  A successful shift to the M2 
phenotype was seen on day 6 for both ages (Figure 3.7). Interestingly, there was a significant 
reduction in both M1 and M2 response of old macrophages to stimuli as compared to 
macrophages derived from the younger animals. 
 
3.4. Discussion  
Older individuals are at risk for increased falls, are more likely to suffer from fractures 
and have delayed bone healing due to an extended inflammatory response during fracture healing 
[6, 64, 290]. Inflammatory processes regulate skeletal cell activity through the release of 
cytokines and chemokines secreted by macrophages [158, 291, 292]. There is a need for 
therapeutic approaches that modulate impaired aged macrophage polarization to improve bone 
regeneration outcomes in older patients.  A variety of strategies to activate M1 or M2 
macrophage phenotypes have been pursued in the context of improving osteogenesis [154, 155, 
263, 293, 294], but very few studies have been conducted in elderly animals that have impaired 
macrophage responses.  Inhibition of inflammatory macrophages in elderly mice with fractures 
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was reported to prevent delayed healing of old mice [295].  That study administered macrophage 
modulating drugs to the mice to improve bone formation via systemic delivery for 10 days in 
their food.  The novelty of the present study was to design a localized delivery system using 
factors known to positively influence osteoblast differentiation and to guide the transition of 
macrophages. Both the bCaP coating and SIMV contribute positively to new bone formation 
[164, 296-298].  This work paves the way for application of the bCaP delivery system to bone 
grafts which could be placed in open fractures or bone defects as a means to locally, in a site 
specific way, without systemic side effects, control host macrophage response and concurrently 
improve bone formation.   
It is known that the aging process impairs the initiation of the M1 response and delays the 
M2 polarization in response to stimuli [121, 122, 270, 279, 299]; however, to our knowledge 
there are no studies that have evaluated the effects of locally delivered therapies from a 
biomaterial on aged macrophage modulation. In the present study we confirmed the ability of a 
bCaP biomaterial coating to polarize the impaired old mouse macrophages BMDM with 
sequential delivery of IFNγ followed by SIMV from bCaP in highly localized manner.  Despite 
no measurable release of IFNγ or SIMV, there were measurable effects on the cells. It has been 
shown previously that the addition of a bCaP barrier layer to a poly-L-lysine/poly-L-glutamic 
acid polyelectrolyte multilayer coating effectively provided highly localized, cell mediated, 
sequential delivery of two biomolecules to osteoprogenitor cells [204], but it was unknown if 
bCaP alone could deliver two molecules and temporally guide macrophage polarization. 
The physical and chemical properties of the biomaterial can influence macrophage 
modulation. For example, it has been reported that calcium and strontium ions on a nanostructure 
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titanium surface can increase M2 macrophage phenotype [300]. Another study reported that 
hydroxyapatite granules activate some M1, but more M2 activation of THP-1 cells [301]. In the 
present studies, the bCaP coating, which is carbonated hydroxyapatite in the form of a coating 
rather than in granules, was a potent M1 stimulator for THP-1 cells. An appropriate amount of 
inflammation and granulation tissue formation is a prerequisite for healthy and successful bone 
healing outcome, so the M1 stage is essential.  Furthermore, given the ability of M1 
macrophages to stimulate angiogenesis during tissue regeneration [264, 302], the enhanced M1 
macrophage phenotype induced by the bCaP coating may contribute positively to tissue repair.  
The underlying mechanism by which SIMV modulates macrophage phenotype has not 
been fully elucidated, but it is known that SIMV reduces pro-inflammatory cytokines that drive 
the M1 phenotype [177, 285-287]. Our results suggest that the dose of SIMV we tested promotes 
a hybrid M2 phenotype, characterized by both M2a and M2c markers (CCL17 and CD163, 
respectively), which could be mediated through its increase in IL10 [286, 287]. However, a slight 
increase in expression of two of the M1 markers was seen at the 10 g dose of SIMV tested. It 
has been reported that SIMV caused swelling and inflammatory tissue reactions at milligram 
doses when implanted in rats [193, 194]. Further in vitro and in vivo dose response studies are 
needed to determine how to optimize the balance between inflammation and the resolution of 
inflammation in order to get a net gain during osteogenesis in older animals. 
The phenotype of a macrophage changes over time to control bone healing events [39, 
193, 194, 302-305]. The importance of the timing of macrophage modulation to osteogenesis 
was demonstrated in vitro by pipetting in IL-4 to M1-macrophages co-cultured with 
osteoprogenitors [293]. Only the delayed addition of IL-4 enhanced osteoblastic differentiation 
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as compared to its immediate administration.  Appropriate temporal control over macrophage 
polarization is required to achieve the pro-anabolic contributions of macrophages to bone repair.  
The bCaP biomaterial system tested in the present studies provided a similarly timed, delayed 
modulation of macrophage polarization and thus may be an ideal design to promote osteogenesis.  
However, this study did have some limitations. First, we only evaluated gene expression of a 
handful of M1 and M2 markers, but not protein or functional level. Although gene expression 
has been shown in multiple studies to be a very thorough way to phenotype macrophages [306], 
it is not known if the M1 and M2 phenotypes promoted by the bCaP delivery system will 
translate to optimal biological activity and capable of inducing in vivo bone repair in old mice. 
These limitations notwithstanding, the results of the present study advance the design of 
immunomodulatory biomaterials that can modulate the behavior of aged macrophages. 
 
3.5. Conclusions 
The dysfunctional macrophage of the older person is a target for new approaches to improve 
bone formation and accelerate repair of bone injuries in the older person. These studies showed 
that a bioinspired apatite coating is an effective means of temporally separating delivery of an 
M1 macrophage-promoting stimulus from an M2 macrophage-promoting stimulus, resulting in 
effective M1-to-M2 phenotype transitions of THP-1 macrophages.  The delivery of IFNγ 
followed by SIMV from bCaP was shown to successfully guide macrophage phenotype 
transitinos in a macrophage cell line from a young human, as well as primary macrophages 
derived from adult and old mice.  These findings suggest that delivery of immunomodulatory 
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molecules from bCaP is a valuable strategy that should be pursued as a means of increasing bone 
formation in older patients who suffer from age-related impairments in macrophage function.  
 
Table 1 PCR primer sequence 
Human peripheral blood THP-1: Housekeeping gene  
Gene Forward Sequence  Reverse Sequence 
GAPDH AAGGTGAAGGTCGGAGTCAAC GGGGTCATTGATGGCAACAATA 
Human peripheral blood THP-1: M1 Markers    
Gene Forward Sequence  Reverse Sequence 
CCL1 GATGCTGAACAGTGACAAATC TCAGGAACAGCCACCAGTG 
CXCL11 GACGCTGTCTTTGCATAGGC GGATTTAGGCATCGTTGTCCTTT 
CXCL10 ACACTAGCCCCACGTTTTCT GAGAGGTACTCCTTGAATGCCA 
Human peripheral blood THP-1: M2 Markers    
Gene Forward Sequence  Reverse Sequence 
GAPDH CAGTGCCAGCCTCGTCCCGTAGA CTGCAAATGGCAGCCCTGGTGAC 
CD163 TTTGTCAACTTGAGTCCCTTCAC TCCCGCTACACTTGTTTTCAC 
CCL17 CGGGACTACCTGGGACCTC CCTCACTGTGGCTCTTCTTCG 
CD206 AAGGCGGTGACCTCACAAG AAAGTCCAATTCCTCGATGGTG 
Mouse :  Housekeeping gene  
Gene Forward Sequence  Reverse Sequence 
Gapdh CAGTGCCAGCCTCGTCCCGTAGA CTGCAAATGGCAGCCCTGGTGAC 
Mouse: M1 Markers 
Gene Forward Sequence  Reverse Sequence 
Cxcl11 AGTAACGGCTGCGACAAAGT GCACCTTTGTCGTTTATGAGC 
Nos2 AAACCCCTTGTGCTGTTCTC ATACTGTGGACGGGTCGATG 
IL1 TTCAGGCAGGCAGTATCACTC GAAGGTCCACGGGAAAGACAC 
Mouse: M2 Markers 
Gene Forward Sequence  Reverse Sequence 
Arg1 GCAGAGGTCCAGAAGAATGG AGCATCCACCCAAATGACAC 
Ccl17 TGCTTCTGGGGACTTTTCTG  CATCCCTGGAACACTCCACT 
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Figure 3.1: Evaluation of the kinetics of THP-1 macrophage access to the cytotoxic AntiA 
molecule below the biomimetic calcium phosphate (bCaP) barrier coating.  (A) Schematic 
representation of the bCaP coating and AntiA location. (B) Quantified percent LIVE® stained 
area of THP-1 cells on bCaP coating (**** P< 0.001). (C) Fluorescent LIVE® stained images of 
cells cultured on bCaP alone (-A) as compared to cells cultured on bCaP-AntiA (+A) at over 
time in culture. Scale bar = 100 μm. 
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Figure 3.2: Gene expression of human THP-1 macrophages cultured on bCaP as compared to 
non-tissue culture-treated polystyrene (PS) on day 1 and day 6 of culture. (A-C) M1 macrophage 
markers. (D and E) M2 macrophage markers. qRT-PCR data presented as fold change over the 
housekeeping gene GAPDH. * P< 0.05. 
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Figure 3.3: Simvastatin dose response study. Gene expression of human THP-1 macrophages 
cultured on bCaP with either 2 or 10 g SIMV beneath the bCaP with LPS and IFNγ in the 
media for the first three days.  (A-C) M1 macrophage markers and (D and E) M2 macrophage 
markers. (F) Schematic representation of the experimental configuration. qRT-PCR data 
presented as fold change over the housekeeping GAPDH and normalized to M0 macrophages 
cultured on bCaP without drug. * P< 0.05. 
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Figure 3.4: IFNγ dose response study in combination with 10 g SIMV. Gene expression of 
human THP-1 macrophages cultured on bCaP with IFNγ on the exterior and SIMV below the 
bCaP barrier layer. (A- C) M1 macrophage markers. (D and E) M2 macrophage markers. Data 
presented as fold change over the housekeeping gene GAPDH. * P< 0.05. 
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Figure 3.5: Gene expression for THP-1 cultured on bCaP surface with or without 250 ng IFNγ or 
10 g SIMV or both over 6 days. (A-C) M1 macrophage markers and (D and E) M2 macrophage 
markers. (F) Schematic representation of the sequential delivery system. * P< 0.05. 
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Figure 3.6: Gene expression of old murine bone marrow derived macrophages over time when 
cultured on bCaP with 250 ng IFNγ on the exterior and 10 g SIMV below the bCaP barrier 
layer as compared to culture on the bCaP layer only.  (A-C) M1 markers. (D and F) M2 markers. 
* P< 0.05. 
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Figure 3.7: A comparison of the gene expression of primary bone marrow macrophages from 
young adult and old mice during culture on bCaP with 10 g SIMV below the bCaP barrier 
layer. The M1 stimuli LPS and IFNγ were in the culture medium for the first 3 days. (A-C) M1 
macrophage markers. (D, E) M2 macrophage markers. Data normalized to GAPDH and then 
expressed as fold change over M0 macrophages cultured on bCaP. * P< 0.05. 
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Chapter 4 
Delayed Delivery of Simvastatin Increases Osteogenesis of Older human 
Osteoprogenitors 
4.1 Introduction 
Aging can cause a decline in regenerative potential of tissue and cellular functions in a 
variety of organs [307]. MSCs can differentiate under appropriate stimuli to osteoblasts, 
adipocytes, chondrocytes, and myocytes [308]. The regeneration potential of mesenchymal stem 
cells (MSCs) diminishes with advanced age and this contributes to changes in cellular functions. 
Several reports indicate that aging is accompanied reduction in number, proliferation, and 
osteogenic differentiation capacity [79, 85, 309, 310]. Therapeutic strategies that target altered 
cells of the older patient are needed to achieve youthful bone healing. 
MSCs have an ability to mediate tissue repair, and their potency to do so is improved by 
the presence of inflammation at the site of injury [307]. To better understand the effect of 
inflammation on MSCs, several studies attempted to explore in vitro MSC-macrophage cross-
talk [293, 311]. Macrophages were found to induce osteoblast differentiation and matrix 
mineralization of human MSCs while inhibiting unwanted adipogenesis [293, 311]. Similarly, 
M2 macrophages and their associated cytokines were shown to support the growth of hMSCs, 
while M1 macrophages and their associated cytokines inhibited the growth of hMSCs in vitro 
[40]. These data imply that providing a pro-reparative (M2) environment via localized delivery 
of therapeutic agent could be an effective strategy to maximize MSCs differentiation.  
During senescent cells undergo irreversible growth arrest, but continue to be 
metabolically active and undergo characteristic changes in gene expression [132]. The senescent 
74 
 
 
cells can be examined by senescence-associated secretory phenotype (SASP) of senescent cells 
can be detected by senescence-associated β-galactosidase (SA-β-gal) activity and they are 
associated with the secretion of a variety of inflammatory cytokines and growth factors [312]. 
The highest senescent cell secreted factors are IL-4, IL-6, IL-8, IFN and , Transforming 
Growth Factor Alpha (TGF), and Monocyte Chemotactic Protein-1 (MCP1) [313-315]. These 
are factors associated with chronic systemic inflammation present known as inflammaging and 
immunosenescence [reviewed in [316, 317]].  For example, IL1, TNFα and TNFβ are all linked 
to decreased MSC mineralization and increased bone resorption [318-320]. It has also been 
reported that the increased production of IL-6 by mouse, rat and human osteoblasts was 
associated with osteoporosis in postmenopausal women [321]. The potential effect of 
inflammatory cytokines on osteoprogenitor differentiation needs to be considered for optimal 
bone repair of older patients. 
In the previous chapter we tested SIMV as an immunomodulator to modulate 
macrophage phenotype and shift them to the pro-reparative state. Beside SIMV’s ability to serve 
as an anti-inflammatory agent [282, 283]; it stimulates bone morphological protein (BMP-2), 
increases recruitment and differentiation of osteoblasts precursors in dose-dependent manner, 
reduces osteoclast activity [322-329] and improves bone healing [188, 189]. In this chapter, the 
effect of delayed delivery of SIMV on cytokine expression and osteogenesis of older human 
osteoprogenitors was investigated. Based on SIMV properties, we hypothesized if pro-
inflammatory cytokines negatively impact osteogenic differentiation, then delivery of anti-
inflammatory SIMV, after the requisite pro-inflammatory phase, will modulate cytokines 
produced by osteoprogenitors and increase osteogenesis.  
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4.2 Materials and Methods 
4.2.1 Delivery System 
The bCaP coated disks were prepared using SBFx5 method, described in chapter 2. Prior 
to bCaP coatings, 10 μl of either 200 ug/ml or 1000 ug/ml (2 or 10 μg/disk) of SIMV in prodrug 
form was adsorbed onto the sandblasted plastic disks and allowed to completely dry to maximize 
binding.  A stock solution was made by dissolving 10 mg of simvastatin compound (Sigma, 
PHR1438) in 1ml of 95% ethanol then diluted to the desired concentration with 95% ethanol. A 
fresh stock solution was made per each study. The bCaP coated disks were sterilized prior to cell 
culture by exposure to UV light for 10 min to each side.   
 
4.2.2 Cell Culture on TCP 
Human mesenchyme-derived progenitor cells (HMDPCs) were isolated from older 
human bone discarded during orthopedic surgery to treat arthritis in the hand. Bone chips were 
cut into small pieces and cultured in Alpha-MEM (#12561), 10 % FBS, L-glutamine (2 mM) and 
1% Antibiotic/anti-mycotic. Cells began to migrate out of bone chips within 1 week in culture 
and reach confluence after 3-4 weeks.  Previous studies showed that the flow cytometry markers 
of these MSC-like cells matched standard phenotype of MSCs obtained from bone marrow 
aspirates [111, 330]. Age-related changes observed in bone chip progenitor cells and fewer 
osteoprogenitors with altered receptors [309]. Patients on many medications are not selected for 
studies. 
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Cells used for Active -hydroxy acid, SIMV-A dosing study: The -hydroxy acid form of 
simvastatin (SIMV-A) was directly pipetted into osteoprogenitor cultures at 15,000 cell/cm
2
 in 
12-well tissue culture treated plate (Corning Inc., Corning, NY) at multiple time points.  In the 
present SIMV-A studies, cells at passage 2 were detached from tissue culture dishes with 0.25% 
trypsin and 1 mM EDTA (Invitrogen, Cat. No. 25200-056) at 37°C. Cells were counted using an 
automated cell counter (Bio-Rad, TC20) with trypan blue staining to assess cell number and 
viability. Osteoprogenitors were seeded at 15 x 10
3
 cells/cm
2
 in 12-well tissue culture treated and 
proliferated to confluency in Alpha-MEM (#12561), 16.5 % FBS, L-glutamine (2 mM) and 1% 
Antibiotic/anti-mycotic. Medium was then switched to osteogenic medium on day 7 of culture. 
Osteogenic medium consisted of the same proliferation media ingredients plus dexamethasone 
(10nM), -glycerophosphate (20mM) and Ascorbic acid-2 phosphate (50 uM). Osteogenic 
medium was replaced twice a week until day 21 or day 30.  
-hydroxy acid SIMV addition (timing and dose): Either 0.5 nM/ml or 10nM/ml SIMV-
A or vehicle were directly pipetted into the culture wells started at either 4-hour, day 3 or day 7 
and given twice a week until day 21 or day 30. Before addition to cultures, SIMV was converted 
from its lactone prodrug form to its active -hydroxy acid open ring form (SIMV-A) following 
previously described method (37). Briefly, 21 mg of simvastatin compound (Sigma, PHR1438) 
was dissolved in 0.5 ml of 95% ethanol followed by the addition of 0.75 ml of l N NaOH. The 
solution was heated at 50 ˚C for 2 hours. Then the resulting solution was neutralized with l N 
HC1 to a pH of 7.2 and brought up to a volume of 5 ml with distilled water, and stored in 
multiple aliquots at -20°C until use. The final concentration was 10 mM. SIMV-A was diluted 
with culture medium and added to cell cultures.  This study was repeated with cells obtained 
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from three female patients (66, 70 and 73 years old) with fresh -hydroxy acid SIMV solution 
made per each study.  
 
4.2.3 Cell Culture on bCaP 
After SIMV adsorption followed by bCaP application, disks were UV sterilized and then 
placed into 12-well non-treated tissue culture plates (Corning Inc., Corning, NY) and incubated 
in α-MEM medium for 30-45 minutes prior to cell culture. Osteoprogenitors (derived from older 
donor age 62-78 female) were seeded at 3 x 10
4
 cells/cm
2
 in proliferation medium and then 
incubated at 37°C and 5% CO2 .  Osteogenic medium was then used on day 7.  Culture medium 
was refreshed twice a week until day 30.  
 
4.2.4 Cell Characterization 
The percentages of senescent cells and Cytokines level: Bone chip progenitors derived 
from 78 years old donor were cultured in Alpha-MEM (#12561), 10 % FBS, L-glutamine (2 
mM) and 1% Antibiotic/anti-mycotic. SBGA staining was performed on day 2 of culture using 
Senescence Cells Histochemical Staining Kit (Sigma, USA, Cat# CS0030) following 
manufacture’s protocol. Total of eight images per well (3 wells total) were taken using an 
inverted microscope (TE300, Nikon) equipped with a camera (Diagnostic Instruments), and 
imaging software (Spot Insight, Nikon).  The total number of cells and the blue-stained cells 
(senescent cells) were counted and the percentage of cells expressing SBGA staining was 
calculated manually over total number of cells. 
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Osteogenic differentiation on TCP: Mineralized nodules in osteogenic cultures were 
stained with the calcium dye xylenol orange (XO) (Sigma, St. Louis, MO) for a final 20 µM 
concentration. The plates were evaluated for the XO-stained nodules under a fluorescence 
microscope. Calcium content at day 21 or day 30 were also evaluated using (Eagle Diagnostic, 
Cat#2400-1) according to manufacturer’s instructions. A panel of inflammatory (IL1, IL6, 
TNF and IL10) and osteogenic genes (BSP, OCN) was also evaluated. 
Proliferation and osteogenic differentiation on bCaP: The proliferation of cells cultured 
on bCaP was evaluated with CellTiter-Blue® (Promega, Madison, WI, USA), fluorometric 
method for estimating the number of viable cells present on bCaP coated disks. A panel of 
inflammatory (IL1, IL6, TNF and IL10) and osteogenic genes (COL1A1, BSP and OCN) was 
also evaluated since mineral deposition cannot be conducted due to the cell culture on calcium 
rich bCaP. 
Data Analysis: Quantitative PCR was conducted on a panel of inflammatory cytokines 
and osteogenic genes and normalized to GAPDH and baseline, 4hrs time point for cytokines and 
day 7 for osteogenic, using 2−∆∆𝑡 method. Inflammatory cytokines experiments, all cytokines 
were analyzed after three days of SIMV-A dosing in all groups. To measure osteogenic genes, 
data were normalized over GAPDH and over day 7 time point.  
All Quantitative PCR assays was performed by isolating total RNA from the cells using 
Total RNA was extracted from the dishes by using TRIzol reagent (Invitrogen Life 
Technologies, CA, USA) then three micrograms of RNA were reverse transcribed into cDNA 
using (Cat# 639543, Takara, Japan) and thermocycler (BIO-RAD Laboratories Inc., CA, USA) 
followed by quantitative PCR using iTaq™ universal SYBR® Green supermix kit (BIO-RAD 
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Laboratories Inc., CA, USA) on a MyiQTM instrument. Primer sequences can be found in table 
4.1. In SIMV-A addition experiment, inflammatory genes were normalized to GAPDH and to 
non-treated cells before SIMV-A addition using 2−∆∆𝑡 method, where ΔΔCT is the result of 
subtracting [CT gene − CT GAPDH] (non-treated cells before SIMV-A addition) from [CT gene 
− CT GAPDH] (experimental group).  
 
4.2.3 Statistical Analysis 
Statistical analysis performed using t-tests if there are two groups or by one-way 
ANOVA (P<0.05) with Tukey post-test (t:test) for 3 or more multiple groups (using GraphPad 
Prism). 
 
4.3 Results 
4.3.1 Senescence Cell Percentage and Cytokines Level 
To assess the cytokine background levels of older human osteoprogenitors as compared 
to younger osteoprogenitors, gene expression of cytokines of osteoprogenitors derived from 
older, 70 years, was compared to younger female, 44 years, on day 3 and day 10 of culture 
without any drugs. The older osteoprogenitors showed significant elevation in anti-inflammatory 
genes IL1 and IL6 both day 3 and 10 of culture. However, TNF gene expression was 
significantly increased in older donor at day 10 but not on day 3 of culture as compared to the 
younger donor. This study also showed significant reductions in pro-reparative gene IL10 level 
of older osteoprogenitor as compared to younger donor (Figure 4.1 A). 
80 
 
 
To further assess bone chip cells molecular mechanisms underlying the cells ability to 
proliferate and undergo osteogenic differentiation; the percentage of senescence cells present in 
the culture of osteoprogenitors derived from 78 years old female was examined using SABG 
staining. The Senescence β-Galactosidase staining revealed that 80% of the cells obtained from 
the older donor are carrying senescence characteristics (Figure 4.1 B). The results from these 
studies motivated our laboratory to test SIMV, anti-senescence and anti-inflammatory agents, the 
effect on the cytokines production of older human osteoprogenitors in the following experiments. 
 
4.3.2 SIMV hydroxy acid Dose and Timing 
Delayed dosing modulated cytokines: The overall goal of this study was to determine the 
timing of addition and optimal dose of SIMV-A to modulate cytokines and enhance 
osteogenesis. SIMV-A administered starting at 4 hours of culture caused an increase in anti-
inflammatory markers IL1 and IL6 associated with reductions in pro-reparative IL10 level 
compared to control in all three patients tested on day 3 of culture (Figure 4.2A) and Appendix 1 
Figures (1A, 2A, and 3 A).  Administration of SIMV-A starting on day 3 of culture showed no 
changes in cytokines production measured on day 6 as compared to control (vehicle treated at 
day 3) (Figure 4.2B) and Appendix 1 Figures (1B, 2B, and 3B). SIMV-A administered with the 
osteogenic medium on day 7 of culture modulated cytokines production by reducing anti-
inflammatory markers IL1, IL6 and TNF and increased IL10 by 4 folds as compared to control 
and to immediate dosing (Figure 4.2C) data of other patients tested can be found in Appendix 1 
Figures (1C ,2C , and 3C).  
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Delayed dosing enhanced osteogenic differentiation over immediate dosing: To better assess the 
relation between cytokines productions and osteogeneses; dosing of SIMV-A starting at multiple 
time (4hr, day 3 or day 7) was tested to modulate osteogenic differentiation of older human 
osteoprogenitors. The early administration of SIMV-A starting at either 4hrs or day 3 of culture 
,twice a week until day 30, caused suppression in cells ability to produce mineralized nodules as 
measured by XO staining (Figure 4.3 A and B). Low dose of SIMV-A, 0.5 nM, administered 
with osteogenic medium at day 7 , twice a week until day 30,  resulted in more mineralization 
deposited by the cells significantly greater than vehicle and other groups tested in the study as 
seen by XO stained area (Figure 4.3 C). While administration of a higher dose of SIMV-A, 
10nM, blocked cells ability to differentiate and mineralize. Increased Ca+ content, BMP-2 
expression and osteogenic genes, BSP and OCN, were also evidence with delayed addition of 
0.5nM SIMV in cells from the three donors tested (Figure 4.4). Data of other patients tested can 
be found in Appendix 1 Figures (3, 4, 5, 6 and 7). 
 
4.3.3 SIMV prodrug Delayed Delivery from bCaP  
Delayed delivery from bCaP enhanced proliferation and pro-reparative cytokines 
osteogenic differentiation:  
Proliferation:  The objective of this study was to confirm that local delayed delivery of 
SIMV in prodrug form from bCaP delivery system could modulate cytokines produced by older 
human osteoprogenitors as well as their osteogenic response at later point.  Either 2 g or 10 g 
was delayed delivered from bCaP coatings. SIMV delivered from bCaP resulted in significant 
improvement of cell proliferation in dose-dependent manner as compared to cells cultured on 
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bCaP w/o SIMV as seen by CellTiter-Blue® cell viability assay on day 7 of culture (Figure 4.5 
A). Data of other patients tested can be found in Appendix 1 Figures (8A and 10A). 
Cytokines productions: To examine the effect of SIMV prodrug delivered from bCaP 
coatings on cytokines productions; 2 g or 10 g of SIMV was delayed delivered from bCaP and 
gene expression of inflammatory cytokines were measured on day 7. Delivering either 2 g or 10 
g of SIMV from bCaP resulted in significant reduction in early anti-inflammatory cytokines 
IL1, IL6 and TNF of older human osteoprogenitors on day 7 of culture as compared to control 
cultured on drug-free bCaP coated disks in both 62 and 73 years old donors (Fig 4.5B) and 
appendix 1 (Figure 8 B and 10 B). However, one donor, 78YO, showed different response to 2 
g SIMV delivered from bCaP. An elevation in early inflammatory markers, cytokines IL1, IL6 
and TNF, was seen with 2 g SIMV but not to 10 g SIMV (appendix 1 Fig 10 B). Delivering 
SIMV in delayed manner from bCaP also resulted in elevation, up to 8 folds, of the essential pro-
reparative marker IL10 in osteoprogenitors derived from older human female age 62, 70 and 78 
(Figure 4.5 B and appendix 1 Figure 8B and 10 B). 
                Osteogenesis of older human osteoprogenitors: To further test the effect of delayed 
delivery of SIMV from bCaP on osteogenic response of older human osteoprogenitors; 2 g or 
10g, was delivered from under the bCaP coating and resulted in significant elevation of the 
osteogenic genes, COL1A1, BSP and OCN (Figure 4.6) compared to control. The higher dose of 
SIMV, 10 g, resulted in further increases in both proliferation and osteogenic genes than the 
lower dose (2 g) in two patients 62 and 78 years old (appendix 1, Figures 9,10 and 11) . 
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4.4 Discussion 
Immunomodulation and tissue regeneration are closely related essential mechanisms in 
bone regeneration therapy. These biological features are both regulated in response to local 
environmental changes including the presence of senescence cells, growth factors, inflammatory 
cytokines, and other factors. Changes in the microenvironment during the normal aging process 
reduce osteoprogenitor activities [40, 311, 331]. Indeed, our studies showed that 
osteoprogenitors derived from older donors have elevated levels of anti-inflammatory markers 
with a reduction in pro-reparative markers. These cytokines are essential mediators that could 
direct macrophage polarization, osteogenic differentiation and osteoprogenitor behavior in vitro 
[332]. 
The multiple functions of SIMV, anti-inflammatory, anti-senescence and osteogenic 
mediator, made it an attractive molecule for treating compromised bone healing [333]. Previous 
studies have mainly focused on immediate administration of SIMV to cell cultures using high 
doses and cell lines [323-328, 334] or primary MSCs from young animals [335, 336] or young 
humans [337]. These studies have provided valuable information regarding the positive effect of 
SIMV on osteogenesis of cells from young animals or humans. However, we found only one 
study that tested osteogenic effects of SIMV on cells from older bones [322] and that study did 
not investigate anti-inflammatory effects.  Therefore we investigated the combined effect of 
SIMV in terms of delivery timing and dose to increase osteogenic differentiation and reduce 
inflammatory cytokines of the older human osteoprogenitors. Our studies showed effectiveness 
of a lower dose and that a higher dose of SIMV, 10 nM, inhibited cell differentiation, which may 
be associated with the adverse effects that have been shown to result from high doses of 
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simvastatin [192, 322]. Our studies lead us to conclude that control over timing and dose of 
simvastatin is essential for positive effects on either MSC differentiation. 
It is likely that the anabolic effect of simvastatin on older human osteoprogenitors is due 
to increasing BMP-2 expression [338].  BMP-2 binds to a specific receptor (receptor II) at the 
cell membrane and forms a complex that phosphates Smad protein [339]. The phosphorylated 
Smad complex translocates to the nucleus and regulates the transcriptional activity of the target 
genes [340]. BMP-2-induced osteogenesis is regulated by Runx2. A study was conducted with 
mouse MSCs and aimed to clarify the molecular mechanism of simvastatin-induced osteogenic 
differentiation [341]. That study concluded that SIMV induced osteogenic differentiation by 
activating the Ras homolog gene family, member A (RhoA) signaling pathway (primary 
cytoskeleton regulator) and increases cytoskeletal tension, as well as by enhancing cell rigidity 
which all play a crucial role in the osteogenic differentiation of MSCs.  
The age-related alteration in MSC behavior and chronic inflammation associated with 
increased cytokine productions weakens the regenerative capacity of older MSCs. Therefore, it is 
likely that the successful regeneration of bone will require controlled, appropriately timed 
reduction of important inflammatory cytokines. Our findings support this and show that the early 
reduction of key pro-inflammatory cytokine genes, IL1β, IL6 and TNFα, can have profound 
consequences for older progenitor cells and allowing them to differentiate and proliferate 
normally. Furthermore, we demonstrated that delayed delivery of simvastatin from bCaP 
coatings modulate inflammatory markers and promoted osteoblastic differentiation of older 
human. Previous studies have reported beneficial bone anabolic effects expected from lower and 
sustainable release of simvastatin. Various biomaterials, including poly(L-lactic acid) (PLA), 
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poly(lactic-co-glycolic acid) (PLGA), calcium sulfate, hyaluronic acid, gelatin and 
methylcellulose have been investigated for the local administration of simvastatin with slow-
release [190, 342-346]. However, there are disadvantages to the use of hydrophobic carriers such 
as PLA or PLGA including increase inflammatory host-responses in the body and harmful 
byproduct from polymer degradation [347, 348]. 
The design of biomaterials with better biocompatibility for the sustained delivery of 
water-insoluble simvastatin remains a challenge. Therefore, multiple efforts have been made to 
use alternative to a polymer by the use of β-Tricalcium Phosphate with PCL-co-PEG copolymers 
to deliver SIMV [349]. Furthermore, the incorporation of SIMV in hydroxyapatite microspheres 
resulted in increased osteogenesis and angiogenesis in vitro [194, 350]  and in vivo [351-353]. 
Similarly, the incorporation of SIMV with calcium phosphate coating or powder enhanced 
osteogenic potential after intramuscular and endosteal implantation in rabbits [354, 355].  
However, these attempts were made by using calcium phosphate as a carrier for SIMV and 
resulted in immediate delivery rather than delayed delivery to maximize the beneficial effect of 
SIMV to improve bone repair. To our knowledge, this is the first report that examined the 
delayed delivery of simvastatin from bCaP on the proliferation and differentiation of older 
human MSCs.  
Our results suggest that simvastatin is an osteoinductive drug that can increase osteogenic 
differentiation of MSCs and that delayed delivery from osteoconductive biomaterial coating may 
improve bone tissue regeneration. We proved that delayed delivery of simvastatin, in the prodrug 
form, by the bCaP coating increased in vitro pro-reparative IL10, proliferation and osteogenic 
differentiation of older human osteoprogenitors derived from bones of female patients ranging 
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between 62 to 78 years old.  There was variation in gene expression between the patient samples 
tested.  For example, for the 62 year old patient, the OS genes were elevated in both 2ug and 
further elevation with the 10 g SIMV from bCaP.  The osteogenic genes of the 78 year old 
sample were only elevated with 10 g, but not with 2ug indicating a reduced sensitive to SIMV 
with age. These variations need to be confirmed with additional patient samples, but are beyond 
the scope of this study and remain for further investigation.  
 
4.5 Conclusions 
The goals of the studies were to: (a) determine if delayed active SIMV-A administration 
would modulate cytokines production and induce osteogenesis in human bone chip 
osteoprogenitors and (b) to determine if delayed inactive SIMV delivery from a novel 
biomaterial bCaP coating could modulate osteogenesis. A 0.5 nM solution dose added to the 
media with a 7 day delay from plating was found to decrease anti-inflammatory markers, 
increase pro-reparative IL10 and increase osteogenesis more than vehicle and other groups tested 
in the study as seen by increased XO staining and osteogenic gene expression. Experiments with 
osteoprogenitors grown on SIMV embedded under bCaP resulted in successful modulation of 
cytokines and increased in osteogenic differentiation with delayed access to SIMV not seen 
without SIMV. This approach with delayed delivery of SIMV from novel biomaterial coatings 
has potential to enhance older patients bone regeneration with the ability to reduce unwanted 
extended inflammation time seen in older patients with bone injures. 
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Table 4.1 Human primer sequence 
Primer  Forward  Reverse  
GAPDH AAGGTGAAGGTCGGAGTCAAC  GGGGTCATTGATGGCAACAATA 
IL1 TTCGACACATGGGATAACGAGG TTTTTGCTGTGAGTCCCGGAG 
IL6 Thermo scientific Primer ID: Hs00174131 
IL10 GACTTTAAGGGTTACCTGGGTTG TCACATGCGCCTTGATGTCTG 
TNFα AAGCACACTGGTTTCCACACT TGGGTCCCTGCATATCCGTT 
BMP-2 TTCGGCCTGAAACAGAGACC CCTGAGTGCCTGCGATACAG 
COL1A1 GAGGGCCAAGACGAAGACATC CAGATCACGTCATCGCACAAC 
BSP GAACCTCGTGGGGACAATTAC CATCATAGCCATCGTAGCCTTG 
OCN CATGAGAGCCCTCACA AGAGCGACACCCTAGAC 
 
88 
 
 
 
 
 
Figure 4.1: Age-related changes in osteoprogenitors (A) RT-qPCR cytokines gene expression. 
older human osteoprogenitors, 73 years old, as compared to younger cells, 44 years old. Data 
presented as fold-change over 4hrs baseline. Statistical analysis was performed using GraphPad 
software. t: test analysis of each gene of young vs old was performed and a P< 0.05 was 
considered significantly different. (B) β-Galactosidase (SABG) senescent staining of 
Osteoprogenitors obtained from 78 Years old female bone chip cells culture Scale bar=200um. 
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Figure 4.2: RT-qPCR cytokines gene expression of inflammatory cytokines of 66 years old 
human osteoprogenitors treated with SIMV-A. (A). Day 3 gene expression of inflammatory 
cytokines with SIMV-A given at 4hrs and continues twice a week until day 21. (B). Day 6 gene 
expression of inflammatory cytokines with SIMV-A given at day 3 continues twice a week until 
day 21. (C) Day 10 gene expression of inflammatory cytokines with SIMV-A given at day 7 
continues twice a week until day 21. Data presented as fold-change compared to 4hrs baseline. 
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Statistical analysis was performed using GraphPad software. t: test analysis of each time point 
was performed and a P< 0.05 was considered significantly different. 
 
 
Figure 4.3: XO staining of human osteoprogenitor 66 years old , passage 2 seeded cells at 15,000 
cells/cm
2
, treated with SIMV-A at various timing. Green frame indicates the start time of SIMV-
A treatment. A) 0.5nM of simvastatin was pipetted after 4hrs of culture and continued twice a 
week until day 30. B) 0.5nM of simvastatin was pipetted on day 3 of culture and continued twice 
a week until day 30. C) 0.5nM or 10 nM of simvastatin was pipetted with osteogenic medium on 
day  7 of culture and continued twice a week until day 30. Scale bar 100 um. 
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Figure 4.4: Calcium content and gene expression of human osteoprogenitor 66 years old treated 
with SIMV-A at various timing showing enhanced osteogenesis by delayed SIMV-A as 
measured by (A) Calcium content on day 30 of culture. (B, C, D) Osteogenic genes (BSP, OCN 
and BMP-2) with low dose ,0.5nM, given at day 7 as compared to higher dose given at the same 
time. Data presented as fold-change compared to day 7 baseline. Statistical analysis was 
performed using GraphPad software. Two way ANOVA multiple comparison analysis was 
performed and a P< 0.05 was considered significantly different (*P< 0.05 , ****P= < 0.0001 ). 
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Figure 4.5: Human osteoprogenitor 62 years old seeded on bCaP coated disks (C) or (S) 2 g or 
10 g SIMV-bCaP. (A) AlamarBlue cell proliferation assay (B) Gene expression anti-
inflammatory markers (IL1, IL6 and TNF) and pro-reparative  IL10. Data presented as fold-
change compared to control. Statistical analysis was performed using GraphPad software. Two 
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way ANOVA multiple comparison analysis of each gene was performed and a P< 0.05 was 
considered significantly different. 
 
Figure 4.6: Osteogenic gene expression of Older human osteoprogenitor (62 YO) with delayed 
delivery of 2 g or 10 g SIMV from bCaP. (A) COL1A1. (B) BSP and (C) OCN. QPCR 
presented in fold change over day 7 (baseline) using 2-ΔΔCT. Statistical analysis was performed 
using GraphPad software. Unpaired t: test analysis of each time point was performed and a P< 
0.05 was considered significantly different. 
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Chapter 5 
Summary and Future Directions 
5.1. Summary  
The field of tissue engineering has developed rapidly over the past decade. There are 
numerous reports on various tissues grown in vitro including bone, cartilage, ligament, muscle 
and blood vessels. One of the key objectives of bone tissue engineering is the enhancement and 
guidance of osteogenic differentiation of stem cells within the implanted scaffold. Since 
macrophages have a major impact on the long term outcome of bone repair, ideal scaffolds 
should support and direct the activities of both cell types (osteoprogenitors and macrophages). 
Although many polymeric, ceramic, and composite scaffolds have been produced by a variety of 
methods, there is no delivery system that has been reported to be able to provide temporal 
control over two biomolecules to macrophages, as well as to osteoprogenitors. The primary goal 
of this research was thus to enhance bone healing by modulating macrophage phenotypes with 
the delivery of immunomodulatory agents from a biomimetic calcium phosphate delivery 
system. bCaP has many of the properties of an ideal bone tissue engineering scaffold including: 
supports osteoblast and MSC attachment, proliferation, and mineralization.  
To achieve this goal, the modulation of macrophage phenotypes and osteogenic 
differentiation by therapeutic agents delivered from biomimetic calcium phosphate coatings was 
tested. In chapter 2, delayed delivery of cytotoxic agent, AntiA was tested using RAW 264.7 
murine macrophage cell line. In this study, the biomimetic calcium phosphate coating created via 
a two-step incubation in simulated body fluid x5 successfully provided delayed delivery of the 
embedded factor to macrophages. SEM analysis revealed micro-openings generated by the 
macrophage on day 3 of culture as the mechanism the cells used to access the embedded factor. 
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Cells of the murine osteoblast-like cell line, MC3T3-E1, accessed the embedded factor on day 2 
of culture without creating visible changes in the coating. From these studies, it was concluded 
that the bCaP coatings delivery system can provide time-specific delivery of the therapeutic 
agents embedded beneath the coating.  
The fact that the timing of the delivery from bCaP varied depending on the cell type is a 
key characteristic of bCaP delivery system that must be considered when using it to enhance 
bone regeneration, as well as other regeneration applications. In chapter 3, the bCaP delivery 
system was used to sequentially deliver immunomodulatory agents, IFN followed by 
simvastatin, to macrophages. The novelty of this approach was the use of an FDA approved drug 
as a macrophage modulator, as well as an osteoinductive agent. The sequential delivery of IFN, 
an M1 stimuli, followed by simvastatin, an M2 stimuli; switched both the cell line and primary 
old macrophages from inflammatory phenotypes, or M1, to anti-inflammatory, M2, macrophage 
phenotypes. The studies used multiple cell types, a THP-1 cell line and old murine bone marrow 
derived macrophages, and this revealed differences between each cell type’s responses to stimuli, 
as well as differences in young versus old macrophage response. For example, in the THP-1 cell 
line, gene expression of both M1 or M2 were higher than in primary cells. Furthermore, the 
expression of both M1 and M2 markers was reduced in bone marrow macrophages derived from 
old mice as compared to younger mice, indicating that aging can impair both M1 or M2 
phenotype. 
The delayed delivery of simvastatin from bCaP coatings was found to modulate cytokine 
production by older human osteoprogenitors and enhanced the presence of pro-reparative IL10 
gene expression.  This approach also enhanced the gene expression of BMP-2, bone sialoprotein, 
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and osteocalcin production when cells cultured on simvastatin-bCaP surface over 21 or 30 days. 
Differences in cells derived from multiple patients were noticed emphasizing the importance of 
considering differences in response to therapies by each individual patient. The results from 
these studies indicate the importance of controlling the time of delivery from drug-delivery 
system to induce mineralization in cells delivered from older patients in vitro. These studies also 
provided valuable information about the increased production of cytokines in older cells compare 
to young and the effects of these cytokines on mineralization. In conclusion, the work presented 
in this dissertation indicates that this approach, delayed delivery of simvastatin, has potential to 
be used to heal elderly comprised bone via modulating macrophages response and may one day 
save these patients from potentially long-term hospital stays and repeated, painful orthopaedic 
and dental procedures. 
 
5.2. Key Findings  
On the basis of the results presented in this dissertation, there is significant evidence to 
support the hypotheses outlined in each aim. Namely, drug-delivery system characterization 
(Chapter 2) and macrophages modulation (Chapter 3) studies showed that bCaP can sequentially 
deliver two bio-active factors, such as FGF-2 and AntiA, or IFN and simvastatin, with 3 days 
delay in between the delivery to macrophages.  (Chapter 2; Hypothesis 1) If bCaP serves as 
barrier layer to delay access to a cytotoxic compound, antimycin A, then macrophage or 
osteoprogenitors should show a delayed cell death rather than immediate cell death.  
The use of the bCaP delivery system to deliver immunomodulatory agents to mouse and 
human macrophages (Chapter 3) revealed that simvastatin delivered in delayed manner could 
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switch macrophages from M1 to the M2 pro-reparative state. Chapter 3 Hypothesis: If bCaP 
sequentially delivers IFN and SIMV, then measurements of macrophage phenotypes should 
show a transition from M1 to M2 genes over time. 
Moreover, the delayed delivery of simvastatin from our novel bCaP coating revealed the 
importance of controlling timing and dose of simvastatin to enhance osteogenesis of older human 
osteoprogenitors. Chapter 4 Hypothesis: If pro-inflammatory cytokines negatively impact 
osteogenic differentiation, then delivery of anti-inflammatory SIMV, after the requisite pro-
inflammatory phase, will modulate cytokines produced by osteoprogenitors and increase 
osteogenesis. 
To our knowledge, this is the first study that used bCaP coating to delayed deliver bio-
molecular to macrophages. Previous studies used bCaP coating, alone or in combination with 
other materials, as a carrier to simvastatin which resulted in immediate long term sustain delivery 
of simvastatin to the defect area [194, 204, 352-355]. Other delivery system failed to provide 
sequential timely controlled delivery of macrophage modulating factors [155]. Our work with 
osteoprogenitors is the first report that demonstrates the value of a specific timing of simvastatin 
delivery to restore youthful osteogenesis and proliferation to older human osteoprogenitors. 
Previous studies used much higher doses of simvastatin to induce osteogenic differentiation of 
young cell or cell line [325-327] that could have unwanted side effects. 
Our novel technology is innovative and is anticipated to shift current approaches towards 
an age-specific bioengineered bone graft to treat bone injuries in older patients. In fact, 
modulating macrophage phenotype transitions by time-controlled local delivery of an 
inexpensive, stable small molecule that modifies osteoprogenitors and senescent cell activity is 
novel, cost-effective direction to improve and accelerate bone regeneration in older patients.  
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Redirecting the use of an FDA approved drug as an immunomodulatory factor to enhance bone 
healing in older patients is a cost saving strategy because the safety profile of the drug is already 
known. Since simvastatin delivered from the bCaP coating system could modulate macrophage 
phenotypes, this approach can be used in other applications in immunology or tissue engineering 
that require to a delayed delivery of active biomolecules to modulate macrophages for better 
healing outcomes. 
 
5.3. Future Directions 
Although our approach described here has potential to be applied to create an age-
specific successful bone graft substitute that can provide control over timing of delivery, there 
are still several issues that should be addressed. First, the complete degradation of the bCaP 
coating by macrophages in vitro or in vivo is unknown. A tissue engineered scaffold should 
ideally degrade at a rate complimentary to the rate of tissue ingrowth; however, macrophages 
created micro-opening in the bCaP coating described here on day 3 of culture at a rate depending 
on the cell number. A more comprehensive analysis needs to be performed to examine the 
degradation rate as a function of time, as well as cell number. Fourier-transform infrared 
spectroscopy (FTIR) imaging is one method to examine the coating as it degrades by 
macrophages. The infrared spectroscopy method can be used to map chemical properties of the 
coating and would be able to differentiate between the bCaP and the polystyrene disks material, 
revealed by the micro-openings over time to identify the extent of in vitro degradation at 
multiple time points. 
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The study of immunomodulatory effects of biomaterials on the macrophage combined 
with osteogenic effects is an expanding field. Future studies that investigate cell-cell crosstalk 
between macrophages and osteoprogenitors while being cultured on the bCaP are needed. 
Several studies have characterized the macrophage-osteoblast crosstalk on biomaterial substrates 
in vitro using a cell line or primary cells derived from young humans or animals [33, 293, 356-
361]. More comprehensive investigations of the cross-talk between macrophage and 
osteoprogenitor derived from older human or animal are needed given the increased 
inflammation, inflammaging, and the slower immune response, immune-paralysis, in older 
individuals [316].  
The time-controlled delivery of simvastatin described in our studies showed a promising 
anabolic effect on both macrophage polarization and osteoprogenitor differentiation. Beyond 
incorporation of stimulatory biomolecules, potential biomaterial-based implants that could 
selectively polarize macrophages on their own may prove beneficial. Several studies have shown 
the effect of the biomaterials surface structure and scaffold stiffness to promote M2 polarization 
[362-364]. Scaffold pore size was also shown to affect macrophage response. For example, a 
pore size of 34 μm reduced fibrous encapsulation while larger pore size (160 μm) caused more 
M1 infiltration compared with a smaller pore size [365]. A combination of two biomaterials with 
characteristics to promote M1 first and another biomaterial layered below with structure to 
stimulate M2 subtype could be a viable method to polarize macrophages. Continued research to 
identify cues from biomaterials that can positively interact with immune cells to polarize 
macrophage response following implantation is needed [366]. 
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Appendix 1: Older Human Osteoprogenitors Data 
This appendix represents the in vitro assessment of: 
A- Cytokine production by human osteoprogenitors derived from older patients treated with -
hydroxy acid form of SIMV at either 4 hrs , day 3 or day 7. 
B- Mineralized nodules by human osteoprogenitors derived from older patients treated with -
hydroxy acid addition of SIMV at either 4 hrs , day 3 or day 7. 
C- Osteogenic genes of human osteoprogenitors derived from older patients with -hydroxy 
acid addition of SIMV starting on day 7. 
D- Cytokine production and proliferation response of human osteoprogenitors derived from 
older patients treated with SIMV delayed delivered from bCaP. 
E- Osteogenic genes of human osteoprogenitors derived from older patients treated with SIMV 
delayed delivered from bCaP. 
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Appendix 1-Figure 1: RT-qPCR gene expression of inflammatory cytokines of human 
osteoprogenitors from a 44 year old female treated with SIMV-A. (A). Day 3 gene expression of 
inflammatory cytokines with SIMV-A given at 4hrs showing increased in  (IL1 and IL6 but not 
TNF) and reduced pro-reparative  IL10 as compared to vehicle-treated control. Data presented 
as fold-change compared to 4hrs baseline. (B). Day 6 gene expression of inflammatory cytokines 
with SIMV-A given at day 3 showing no change in cytokines production as compared to vehicle-
treated control. Data presented as fold-change compared to day 3 baseline. And (C). Day 10 gene 
expression of inflammatory cytokines with SIMV-A given at day 7 showing reduction in ( IL1 
and IL6 but not TNF) with increased in pro-reparative  IL10 as compared to vehicle-treated 
control. Data presented as fold-change compared to day 7 baseline. Statistical analysis was 
performed using GraphPad software. t: test analysis of each time point was performed and a P< 
0.05 was considered significantly different. 
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Appendix 1-Figure 2 : Delayed dosing of SIMV-A enhanced pro-reparative cytokines. RT-qPCR 
gene expression of inflammatory cytokines of human osteoprogenitors from a 70 year old female 
treated with SIMV-A. (A). Day 3 gene expression of inflammatory cytokines with SIMV-A 
given at 4hrs showing increased in ( IL1, IL6 and TNF) and reduced pro-reparative  IL10 as 
compared to vehicle-treated control. Data presented as fold-change compared to 4hrs baseline. 
(B). Day 6 gene expression of inflammatory cytokines with SIMV-A given at day 3 showing no 
change in cytokines production as compared to vehicle-treated control. Data presented as fold-
change compared to day 3 baseline. And (C). Day 10 gene expression of inflammatory cytokines 
with SIMV-A given at day 7 showing reduction in ( IL1 and IL6 but not TNF) with increased 
in pro-reparative  IL10 as compared to vehicle-treated control. Data presented as fold-change 
compared to day 7 baseline. Statistical analysis was performed using GraphPad software. t: test 
analysis of each time point was performed and a P< 0.05 was considered significantly different. 
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Appendix 1-Figure 3: Delayed dosing of SIMV-A enhanced pro-reparative cytokines. RT-qPCR 
gene expression of inflammatory cytokines of human osteoprogenitors from a 73 year old female 
treated with SIMV-A. (A). Day 3 gene expression of inflammatory cytokines with SIMV-A 
given at 4hrs showing increased in (IL1 and IL6, but not TNF) and reduced pro-reparative 
IL10 as compared to vehicle-treated control. Data presented as fold-change compared to 4hrs 
baseline. (B). Day 6 gene expression of inflammatory cytokines with SIMV-A given at day 3 
showing no change in cytokines production as compared to vehicle-treated control. Data 
presented as fold-change compared to day 3 baseline. And (C). Day 10 gene expression of 
inflammatory cytokines with SIMV-A given at day 7 showing reduction in (IL1 and IL6 but not 
TNF) with increased in pro-reparative  IL10 as compared to vehicle-treated control. Data 
presented as fold-change compared to day 7 baseline. Statistical analysis was performed using 
GraphPad software. t: test analysis of each time point was performed and a P< 0.05 was 
considered significantly different. 
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Appendix 1-Figure 4: Human osteoprogenitors from a 70 year old female, passage 2, cells 
seeded at 15,000 cells/cm
2
, treated with SIMV-A, initiated at various times. Green frames 
indicate the start time of SIMV-A treatment. A) 0.5nM of simvastatin was pipetted after 4hrs of 
culture and continued twice a week until day 30. B) 0.5nM of simvastatin was pipetted on day 3 
of culture and continued twice a week until day 30. C) 0.5nM or 10 nM of simvastatin was 
pipetted with osteogenic medium on day  7 of culture and continued twice a week until day 30. 
Osteogenesis of older human osteoprogenitors is increased by delayed 0.5 nM SIMV-A as 
measured by XO calcium staining. Scale bar 100 um. 
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Appendix 1-Figure 5: Human osteoprogenitor 70 years old , passage 2 seeded cells on TCP at 
15,000 cells/cm2, treated with SIMV-A at various timing showing enhanced osteogenesis by 
delayed SIMV-A as measured by (A) Calcium content on day 21 of culture. (B, C, D) elevated 
osteogenic genes (BSP, OCN and BMP-2) was observed with the addition of 0.5nM at day 7 of 
culture similar to previous patients. Data presented as fold-change compared to day 7 baseline. 
Statistical analysis was performed using GraphPad software. Two way ANOVA multiple 
comparison analysis of each gene was performed and a P< 0.05 was considered significantly 
different. (*P=0.0142, **P= 0.0028  , ****P< 0.0001  ) 
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Appendix 1-Figure 6: Human osteoprogenitor 73  years old , passage 2 seeded cells on TCP at 
15,000 cells/cm2, treated with SIMV-A at various timing. Green frame indicate the start time of 
SIMV-A treatment. A) 0.5nM of simvastatin was pipetted after 4hrs of culture and continued 
twice a week until day 30. B) 0.5nM of simvastatin was pipetted on day 3 of culture and 
continued twice a week until day 21. C) 0.5nM or 10 nM of simvastatin was pipetted with 
osteogenic medium on day  7 of culture and continued twice a week until day 21. Osteogenesis 
of older human osteoprogenitors is increased by delayed 0.5 nM SIMV-A as measured by XO 
calcium staining. Scale bar 100 um. 
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Appendix 1-Figure 7: Human osteoprogenitor 73 years old , passage 2 seeded cells at 15,000 
cells/cm2 on TCP, SIMV-A added at various timing showing enhanced osteogenesis by delayed 
SIMV-A as measured by (A) Calcium content on day 21 of culture. (B, C) elevated osteogenic 
genes (BSP, OCN and BMP-2) with 0.5nM given at day 7. Data presented as fold-change 
compared to day 7 baseline. Statistical analysis was performed using GraphPad software. Two 
way ANOVA multiple comparison analysis of each gene was performed and a P< 0.05 was 
considered significantly different. (*P=  0.0128 , ***P=  0.0003) 
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Appendix 1-Figure 8: Human osteoprogenitor 70 years old , passage 2 seeded cells at 30,000 
cells/cm2 on C: bCaP coated disks or S: 2 g SIMV-bCaP. (A) Enhanced proliferation in a dose 
dependent manner when cultured on 2 g SIMV-bCaP coated disks as compared to control 
(bCaP only). (B) Decreased in anti-inflammatory markers (IL1b and IL6) with elevation in pro-
reparative  IL10 on day 7 when cultured on 2 g SIMV-bCaP. Data presented as fold-change 
compared to control. Statistical analysis was performed using GraphPad software. t:test 
comparison analysis of each gene was performed and a P< 0.05 was considered significantly 
different. 
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Appendix 1-Figure 9:  Enhanced osteogenic effect of Older human osteoprogenitor (70 YO) with 
delayed delivery of 2 g SIMV from bCaP.  Simvastatin in prodrug form was delayed delivered 
from bCaP older human osteoprogenitors and enhanced osteogenic response as measured by 
osteogenic genes (A) COL1A1. (B) BSP and (C) OCN. QPCR data presented in fold change over 
day 7 (baseline) using 2-ΔΔCT. Statistical analysis was performed using GraphPad software. t: 
test analysis of each time point was performed and a P< 0.05 was considered Significantly 
different. 
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Appendix 1-Figure 10: Human osteoprogenitors from a 78 years old female, passage 2, cells 
seeded at 30,000 cells/cm
2
 on C: bCaP coated disks or S: 2 g or 10 g SIMV-bCaP. (A) 
Enhanced proliferation in a dose dependent manner when cultured on 2 or 10 g SIMV-bCaP 
coated disks as compared to control (bCaP only). (B) 10 g SIMV decreased in anti-
inflammatory markers (IL1b, IL6 and TNFalpha) , (significant increase was observed with 2 g 
SIMV-bCaP coated disks), with elevation in pro-reparative  IL10 on day 7 when cultured on both 
2 g and 10 g SIMV-bCaP. Data presented as fold-change compared to control. Statistical 
analysis was performed using GraphPad software. Two-way ANOVA multiple comparison 
analysis of each gene was performed and a P< 0.05 was considered significantly different. 
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Appendix 1-Figure 11: Enhanced osteogenic effect of older human osteoprogenitors (78 YO 
female) with delayed delivery of 2 g or 10 g SIMV from bCaP.  Simvastatin in prodrug form 
was delayed delivered from bCaP to older human osteoprogenitors and enhanced osteogenic 
response in a dose dependent manner as measured by osteogenic genes (A) COL1A1. (B) BSP 
and (C) OCN. QPCR data presented in fold change over day 7 (baseline) using 2-ΔΔCT. 
Statistical analysis was performed using GraphPad software. t: test analysis of each time point 
was performed and a P< 0.05 was considered Significantly different.  
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Appendix 2: Older Human Macrophage Data 
This appendix represents the in vitro assessment of macrophages derived from peripheral blood 
of older donors (59 and 67 year old females). 
A- Macrophages grown on bCaP as compared to cells grown on polystyrene no drugs. 
B- Single factor delivery from bCaP: either the immediate delivery of 250ng IFN or the 
delayed delivery of 10 g SIMV from bCaP was investigated. 
C- Sequential delivery of 250ng IFN-bCaP- 10 g SIMV was also examined as compared to 
cells grown on bCaP. 
 
Method Primary Older Human Macrophage Isolation: 
Macrophages derived from older human peripheral blood (hPB): Human peripheral blood (from 
females 59 and 67 years old) was used and monocyte were isolated following previously 
described method using double density gradient centrifugations employing Ficoll Isopaque (40, 
41).  Briefly, the blood in 50 mL conical tubes was stratified onto Ficoll-Paque PLUS (Fisher 
Scientific 45-001-749) then centrifuged at 400G for 45 minutes at room temperature. The 
peripheral blood mononuclear cell (PBMC), at the interface between plasma and Ficoll, were 
then collected and diluted in EDTA/PBS and centrifuged twice at 200 g for 15 min. The PBMC 
cells were then plated in RPMI media containing 20% human serum, 1%Pen/Strep in non-treated 
tissue culture dish. After two hours of initial platting, PBMCs were washed with PBS and and 50 
ng/ml human M-CSF was added. Prior to culture on bCaP coated disks, hPBMCs cells were 
cultured for 7 days to allow for monocyte attachment and differentiation to macrophages. After 7 
days, macrophages were gently scrapped and plated on coated disks with or without stimuli 
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(SIMV or IFN or both) at a density of 1 x106 cells/disk. RPMI media containing 10% heat-
inactivated FBS,1%Pen/Strep and 50 ng/ml human M-CSF was used and cells were harvested for 
gene expression on day 1 and day 6 of culture. 
 
Results Primary Older Human Macrophage on bCaP:  
To further examine the effect of bCaP coating on primary macrophages derived from 
older donor, cells behavior grown on bCaP coating was compared to cells grown on polystyrene 
non-treated tissue PS. bCaP alone did not affect either M1 or M2 markers as compared to hPB 
derived macrophages on PS as measured M1 or M2 genes expression of both donors (appendix 
2-Figure 1,2). 
To examine the effects of delivery from bCaP on primary older human macrophage 
phenotypes, either the immediate delivery of 250ng IFN or delayed delivery of 10 g SIMV 
from bCaP was investigated. The delivery of IFN alone from bCaP resulted in elevation of 
CCL1 (M1 marker) during the course of the study day 1 as compared to day 6. However, 
CXCL11 (another M1 marker) was not significantly elevated over time (appendix 2-Figure 3,4 A 
and B). The delayed delivery of 10 g SIMV from bCaP resulted in elevation in M2 markers 
only on day 6 of culture, not seen with IFN delivery (appendix 2-Figure 3,4 C and D).  
To further investigate older human primary macrophage transition from M1 to M2 state, 
the sequential delivery of the two factors (250ng IFN followed by 10 g SIMV) from bCaP was 
also tested using cells from either 59 years old or 67 years old females. The delivery of IFN 
from bCaP before SIMV resulted in elevation of both M1 genes tested, CCL1 and CXCL11, on 
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day 1 of culture as compared to cells grown on bCaP without drugs with cells from 59 years 
(appendix 2-Figure 5 A and B). Only CCL1 , M1 marker, was elevated with IFN delivery to 
macrophages derived from 67 years old female but not CXCL11 (appendix 2-Figure 6 A and B). 
The delyed delivery of SIMV after IFNg from bCaP resulted in elevation of both CD206 and 
CD163 (M2 markers) only on day 6 of culture  on day 6 of culture indicating the delivery of 
SIMV happened in delayed manner (appendix 2-Figure 5 and 6). 
 
Appendix 2- Figure 1: Gene expression of human primary macrophages derived from a 59 years 
old female and cultured on bCaP as compared to non-tissue culture-treated polystyrene (PS) on 
day 1 and day 6 of culture. (A and B) M1 macrophage markers. (C and D) M2 macrophage 
markers. qRT-PCR data presented as fold change over the housekeeping gene GAPDH.  
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Appendix 2- Figure 2: Gene expression of human primary macrophages derived from a 67 years 
old female and cultured on bCaP as compared to non-tissue culture-treated polystyrene (PS) on 
day 1 and day 6 of culture. (A and B) M1 macrophage markers. (C and D) M2 macrophage 
markers. qRT-PCR data presented as fold change over the housekeeping gene GAPDH.  
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Appendix 2- Figure 3: Single factor delivery study. Gene expression of older human primary 
macrophage (59 years old female) cultured on bCaP with either IFNγ on the exterior or SIMV 
below the bCaP barrier layer. (A and B) M1 macrophage markers. (C and D) M2 macrophage 
markers. Data presented as fold change over the housekeeping gene GAPDH. * P< 0.05. 
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Appendix 2- Figure 4: Single factor delivery study. Gene expression of older human primary 
macrophages (from a 59 year old female) cultured on bCaP with either IFNγ on the exterior or 
SIMV below the bCaP barrier layer. (A and B) M1 macrophage markers. (C and D) M2 
macrophage markers. Data presented as fold change over the housekeeping gene GAPDH. * P< 
0.05. 
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Appendix 2- Figure 5: Gene expression for older human primary macrophage (59 years old 
female) cultured on bCaP surface with or without 250 ng IFNγ or 10 g SIMV sequentially 
delivered from bCaP over 6 days. (A and B) M1 macrophage markers and (C and D) M2 
macrophage markers. (F) Schematic representation of the sequential delivery system. * P< 0.05. 
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Appendix 2- Figure 6: Gene expression for older human primary macrophage (59 years old 
female) cultured on bCaP surface with or without 250 ng IFNγ or 10 g SIMV sequentially 
delivered from bCaP over 6 days. (A and B) M1 macrophage markers and (C and D) M2 
macrophage markers. (F) Schematic representation of the sequential delivery system. * P< 0.05. 
 
 
